演講者

Yasmina is an internationally recognized and innovative scientific leader in the field of antibody discovery and biosensors with twenty years of experience in protein engineering and biopharma. To date, she has authored over 45 peer-reviewed publications, had 25 patents granted in the therapeutic antibody space including a market-approved drug (Ajovy), presented over 50 times as an invited speaker globally, and has been involved in numerous industry-wide collaborations and scientific advisory groups. After a twelve-year career at Pfizer where she held positions of increasing responsibility from Principal Scientist to Research Fellow, more recently, Yasmina has held senior management roles at biotechnology companies and contract research organizations including Carterra (CSO), ImmunoPrecise Antibodies (CSO), ALX Oncology (Vice President Protein Science), Revelar (CSO and Co-Founder), and FairJourney Biologics (CTO). During her time as CSO at Carterra, she co-founded its antibody screening biosensor platform (the LSA) which has helped transform label-free interaction analysis in early-stage drug discovery. Yasmina has a Master's degree in Chemistry and a PhD in Biological Chemistry from Oxford University and did post-doctoral studies in biophysical interaction analysis at the University of Utah.

• TS9B: Label-Free Biosensor Tools in Biotherapeutic Discovery: SPR, BLI and KinExA

Dr. Maryam Ahmadi, Director of Cellular & Molecular Biology at Sphere Fluidics, brings over 17 years of comprehensive experience in both industry and academia to her role. With a decade-long tenure at a Contract Research Organization (CRO), Maryam honed her skills in managing diverse projects. Notably, as the former Director of Bioassay at Abzena, she led a team specializing in bespoke Immunology and Bioassay for external clients. Her responsibilities included the development of service lines crucial for testing and de-risking therapeutics, such as PK studies, MHC-associated peptide proteomics (MAPPs), and Cytokine Release Assay for therapeutic antibodies and antibody-drug conjugates. Maryam's expertise spans Immunology and Tumour Biology, underscored by her proficiency in designing and overseeing tailored R&D initiatives. Her academic journey includes a postdoctoral research position at University College London (UCL), where she delved into tumour-specific immune responses. She holds a PhD in Tumour Immunology from the University of Bristol, UK. 

• Using Data Science to Maximise Protein Production

Ph.D. in Veterinary Sciences, with over 10 years of academic, clinical and industrial experience in the field, Dr. Ahmadivand is passionate and dedicated researcher who aims to improve health and welfare through innovative vaccine development. He is currently a Researcher and a former Alexander von Humboldt Fellow at Faculty of Veterinary Medicine, Ludwig-Maximilians-University of Munich. Dr. Ahmadivand has managed and taken an active role of more than 5 research and industrial vaccine projects using various types of vaccines against bacterial and viral pathogens, and 2 national and international molecular epidemiological studies with first reports from Iran of 5 different DNA and RNA viruses, most of which are WOAH listed. He is currently Guest Editor of Vaccines and has also published and patented several results of his research, and received some awards and honors for his academic excellence and innovation. Dr. Ahamdivand has recently developed a vaccine with commercial potential against a WOAH-listed RNA virus (IHNV) using Self-assembling ferritin nanoplatform at LMU Munich (Germany) in collaboration with Institute of Biotechnology and Biomedicine (Spain) and University of Salford (UK).

• Optimising Expression Platforms

At Novo Nordisk, Rahmad enables patients to realize their greatest potential by catalysing antibody design. He leverages experimental data, molecular simulation, and artificial intelligence to build computational oracles and to design antibody therapeutics faster, smarter, and cheaper.

• SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions

Rich Altman has 30 years of experience in protein expression and production. In early 2019, he joined Thermo Fisher Scientific as a Field Application Scientist. Previously, he worked for several pharmaceutical companies, including Amgen, Alexion, Bayer, and Upjohn, on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

• TS9A: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology
• Protein Process Development

More than 25 years of experience in R&D in the pharma industry in Drug Metabolism and Pharmacokinetics (DMPK) within Sanofi. Head of Bioanalysis and Pharmacokinetics section in Discovery for 10 years. Now focused on Biologics, i.e., Antibody-Drug-Conjugates, Multispecific mAbs, or nanobodies for Oncology programs from Discovery to clinic (Phase I) as DMPK project expert with a focus on First-in Human dose selection approaches.

• Antibody-Based Cancer Therapies

Taruna is a seasoned industry leader in biologic drug discovery and development. With a deep understanding from discovery to product approval, Taruna has successfully led teams in creating, designing, and advancement of innovative therapies. She has extensive experience in shaping the portfolio of biologic modalities, including multi-specifics, immune engagers, and antibody-drug conjugates (ADCs). Her strong background in immunology and expertise in biologic drug discovery and development, coupled with knowledge of cutting-edge technology platforms have enabled cross-functional solutions for the programs.Taruna is vice President, Biotherapeutics at BMS. Previously she has served in leadership roles at Amgen, NGM Bio and Coherus.

• Engineering Conjugates
• Machine Learning Approaches for Protein Engineering: Part 1
• Innovative CAR T Therapy
• Emerging Targets and Therapeutic Approaches
• Advancing Multispecifics and Combination Therapy to the Clinic
• Analytical Characterisation of Biotherapeutics
• Optimising Expression Platforms
• Engineering Antibodies & Beyond

I am a curious and driven research scientist with 8 years of active laboratory experience across industry and academia. Over this time, I have become specialized in oncology research, with a particular focus on the tumor microenvironment, immune oncology and T cell engineering. Through my undergraduate placement at AstraZeneca UK, I gained experience in industrial research and multidisciplinary collaboration. Scientifically, I gained knowledge and skills in tumor cell-stromal cell interactions, which I went on to apply to my PhD research, developing a CAR-T cell therapy approach directed at the activated tumor microenvironment. Presently, I am working as a Postdoctoral Researcher in Lausanne, developing novel co-engineering strategies to augment the efficacy of T cell therapies. Throughout my academic experience I have gained and applied key skills in teamwork, problem solving and resilience, as well as a wide range of technical laboratory skills. Additionally, I enjoy connecting with peers and bringing people together scientifically and socially. This is evidenced by my active role in scientific/social/conference committees at each stage of my career so far.

• Innovative CAR T Therapy

Héloïse Audat is a Drug Product Team Leader and laboratory head for Biologics in SANOFI since 2011. She covered all DP fields: formulation and process development, support of technical and clinical manufacturing, coordination of tech transfer including outsourcing activities, global clinical support, in-use studies, medical device compatibility, CMC dossier contributions, and Health Authorities (HA) follow-ups (BLA, MAA, etc.). She has experience in early and late projects on several formats of Biologics including mAb, bi-specific, and Antibody Drug Conjugate. She had previous experience in computerized systems and project management. She holds an engineer diploma specialized in immunology and project management.

• Protein Stability & Formulation

David Ausländer completed his PhD in 2014 at ETH Zürich in Switzerland, where he studied Synthetic Biology and Mammalian Cell Engineering. He joined Novartis in 2017, where he leads a global team in the Biologics Research Center in Cell Line Development. His group develops and applies innovative plasmid- and cell line engineering solutions to enhance quality and productivity of manufacturing cell lines producing New Biologics Entities and Viral Vectors for Cell and Gene Therapies.

• Optimising Expression Platforms

Okan Aydin, Application Scientist at ENPICOM, specializes in bioinformatics and antibody discovery. With a background in bioengineering and bioinformatics, he is dedicated to solving complex biological data problems with simple computational solutions.

• Display of Biologics

Christopher D. Bahl, PhD co-founded AI Proteins in November 2021 and serves as President, Chief Scientific Officer, and Director. Chris is a protein designer, biochemist, structural biologist and entrepreneur. Prior to founding AI Proteins, Chris joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children's Hospital and Harvard Medical School. He pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Dr. David Baker at the University of Washington’s Institute for Protein Design in Seattle. In recognition of his innovative approach to creating therapeutics with the potential to tackle long-standing challenges in medicine and human health, Chris was selected as a 2019 TED Fellow. In addition to his role at AI Proteins, he is the Founder and Co-Organizer of the Boston Protein Design and Modeling Club, a community of computational protein engineers and modelers from both academia and industry and sponsored project of the Open Molecular Software Foundation. He also sits on the Executive Council of The Protein Society, a non-profit scientific and educational organization that provides forums for scientific collaboration and communication and supports the professional growth for early-career investigators. Chris also serves as a Scientific Advisor for Applied Photophysics, Ltd. and BioLoomics, Inc. Chris holds a Ph.D. in Biochemistry from Geisel School of Medicine at Dartmouth, and received his MS in Biochemistry and BS in Biochemistry, Molecular & Cellular Biology from the University of Maine.

• Machine Learning Approaches for Protein Engineering: Part 1

Maurizio Baldassarre holds a degree in biotechnologies and a PhD in protein biochemistry. After his postdoctoral experience at Stockholm University, he joined Merck as a researcher in Pharmaceutical Development of biotech products, focusing on formulation development of NBEs and biosimilars. In 2022, he relocated to Switzerland to set up early-stage drug product development activities at Merck's Biotech Development Center, where he currently currently works. His areas of activities span from screening of Discovery-stage molecules, to formulation and process development, as well as pre-clinical and clinical administration studies.

• Protein Stability & Formulation

Professor Patrick Barth is Associate Professor at EPFL and Adjunct Associate Professor at Baylor College of Medicine, Houston, TX, USA. He received training in Physics, Chemistry and Biology (University of Paris, Ecole Normale Supérieure) in France and performed his PhD at the Commissiariat a l'Energie Atomique in Saclay, France on structure/function studies of membrane proteins (photosystem I) using biochemical and biophysical experimental techniques. He carried out postdoctoral studies at University of California at Berkeley with Tom Alber on computational studies of protein electrostatics and de novo design of peptide inhibitors of cellular protein interactions. He then went to the University of Washington as a postdoctoral fellow and instructor in David Baker's laboratory to develop computational methods within the software Rosetta for predicting and designing membrane protein structures. He started his independent career and received tenure at Baylor College of Medicine and continues at EPFL to marry computation and experiment for understanding the molecular determinants of signal transduction, as well as modeling and designing membrane proteins with novel functions for various synthetic biology and therapeutic applications.

• Antibodies Against Membrane Protein Targets

I am an experienced protein engineer and structural biologist specializing in discovery and optimization of therapeutic candidates isolated from an in vitro platform. I am currently a Senior Scientist II at Adimab, LLC. in Lebanon, NH.Prior to returning to Adimab, I was a PhD student in the laboratory of Dr. Jason S. McLellan at the Geisel School of Medicine at Dartmouth, the focus of my thesis research was on small-molecule and antibody-mediated inhibition of the Respiratory Syncytial Virus and Human Metapneumovirus fusion glycoproteins through biochemical characterization and crystallographic studies. Prior to returning to Dartmouth to obtain my Ph.D. I spent ~10 years in the Biotech industry working for GlycoFi (RA, 2004-2005), Merrimack Pharmaceuticals (RAII, 2006-2008), and Adimab LLC (Scientist I, 2008-2013). During this time, my focus was on protein engineering; specifically, antibody discovery and optimization of therapeutic candidates.

• Optimisation & Developability

I am a researcher with 29 years of experience, working in oncology since 2000, with two domains of expertise, lab head supervising a team of biochemists and cellular biologists, as well as preclinical project head leading teams dedicated to ADC, from target identification to candidate for clinical entry.

• Engineering Conjugates

Andrew Bayliffe, CSO of Marengo Therapeutics, has 25 years of leadership experience in the biopharmaceutical industry, with expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of disease areas. At GlaxoSmithKline Pharmaceuticals, Andrew held senior discovery and development leadership roles in the US and UK and worked on a range of antibody projects including early anti-CD3 antibodies, TCR-based therapeutics, and other immune cell targeted approaches across immunology, respiratory, and oncology therapy areas. Andrew is also a venture partner at ATP (Apple Tree Partners) and an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.

• Engineering the Next Generation of Bispecific Antibodies

Dr. Beaulieu is the co-founder and CSO at Peptomyc, a biotech company developing mini-protein therapeutics for cancer treatment. PhD in Pharmacology with a strong focus on structural biology of proteins, Marie-Eve has led the preclinical pharmaceutical development of OMO-103, the first direct MYC inhibitor to successfully complete a clinical trial showing safety and clinical activity in human patients. Together with the co-founder Dr. Laura Soucek, Marie-Eve designed the company strategy, built the team and fundraised public >11MEur and private ~30MEur capital. She is now in charge of the company's pipeline development and biomarker programs. Marie-Eve has co-authored 8 patent applications, 30 peer-reviewed publications, and 4 book chapters (ORCID 0000-0001-5224-8436). She was awarded several competitive fellowships (e.g., CREFSIP scholarship, MITACS, and FRSQ postdoctoral awards) and contributed to the company’s scientific and business excellence as testified by several local and international awards (e.g., BioFit, best company initiative at AJIEC, EIT Health Headstart, J&J StartUpSlam at BioEurope, and the highly competitive H2020 SME Instrument and EIC Accelerator awards).

• Emerging Targets and Therapeutic Approaches

Dr. Dennis Beringer is an assistant professor at the Center for Translational Immunology at the University Medical Center Utrecht (UMCU), the Netherlands. He obtained his PhD at Utrecht University in the field of structural biology. After which he moved to Monash University, Australia, where he investigated the molecular details of T cell receptor (TCR) - antigen interactions in autoimmune diseases and cancer. Intrigued by TCR biology, he returned to Utrecht to join the group of Prof. Kuball at the UMCU in 2016 to study the molecular determinants of tumor reactive ?dTCRs. Currently, he and his team are focusing on the optimization of existing and the development of novel ?d-TCR based therapeutics for cancer therapy, using protein engineering strategies.

• Next-Generation Immunotherapies

After receiving a Ph.D. in Biochemistry from the University of Keele (UK) in 1991 I worked in the Pharmacology department of University College London, producing and characterizing polyclonal antibodies, producing mammalian heterologous expression systems for electrophysiological studies and ultimately producing recombinant proteins for interaction studies. I then worked for six years at the Oxford protein Production Facility, where we established a HTP clone-to structure pipeline for structural genomics, before moving to Barcelona in 2007 to establish the Protein Expression Core Facility (PECF) in IRB Barcelona. The PECF produces a variety of proteins in E. coli, BEVS and mammalian cells to facilitate the diverse research interests of IRB groups and other members of the local academic community. I am an active member (and current board member) of the Protein Production and Purification Partnership in Europe (P4EU) network.

• Optimising Expression Platforms

Jais Rose Bjelke, PhD, obtained his doctorate in Haemostasias Biochemistry in 2006, following a Master’s degree in Human Biology and a Bachelor’s degree in Molecular Biology. With a tenure at Novo Nordisk of 22 years, he currently holds the position of Principal Scientist and Technology Project Coordinator in the Global Research Unit. Throughout his career, he has played a pivotal role in numerous haemophilia, inflammation and other biopharmaceutical drug projects. Notably, his contributions were instrumental in the research and development of Rebinyn/Refixia (nonacog beta pegol), a long-acting coagulation factor IX drug approved by both the FDA and EMA, and of the coagulation factor VIII-mimicking bispecific antibody Mim8, which is in phase 3 clinical trial.

• Engineering Antibodies & Beyond

Jonathan received his PhD in Analytical Chemistry from Dublin City University in 2007. Jonathan then moved to NIBRT - The National Institute for Bioprocessing Research and Training, working under the mentorship of Prof. Pauline M. Rudd within her GlycoScience Laboratory. In 2010, Jonathan was appointed the John Hatsopoulos Research Scholar within the Barnett Institute of Chemical and Biological Analysis at Northeastern University, Boston, working under the mentorship of Prof. Barry L. Karger. Jonathan returned to NIBRT in 2012 and is the Principal Investigator of the NIBRT Characterization and Comparability Laboratory and an Associate Professor in the School of Chemical and Bioprocess Engineering at University College Dublin.

• Analytical Characterisation of Biotherapeutics

Andreas Bosshart is Senior Director at Molecular Partners heading the DARPin technology platform in the lead generation department. In previous roles he co-developed different therapeutic modalities, including a DARPin ProDrug T cell engager and the Switch-DARPin platform. Andreas is a biochemist by training and obtained his PhD from the ETH Zurich in the group of Professor Sven Panke, working on intensified enzyme-catalysed processes for the production of fine chemicals.

• Engineering Antibodies & Beyond

Andrew Bradbury is Chief Scientific Officer of Specifica. He trained in medicine at the universities of Oxford and London and received his PhD from the university of Cambridge at the MRC Laboratory of Molecular Biology under the guidance of Nobel Laureate, Cesar Milstein. He has worked in the fields of phage and yeast display, library generation, antibody engineering and Next Generation Sequencing for over thirty years. He was a Group Leader at Los Alamos National Laboratory before founding Specifica. Specifica's mission is to enable companies developing therapeutic antibodies with the world’s best antibody discovery platform.

• Display of Biologics

Dr. Ulrich Brinkmann is a member of Roche’s Large Molecule Research organization within Pharma Research & Early Development at the Roche Innovation Center Munich (Penzberg, Germany). His work focuses on protein & antibody engineering, bispecifics, and on delivery platforms for targeted payload delivery. Prior to joining Roche, he served as CSO in functional genomics and pharmacogenetics companies Xantos and Epidauros. His previous work in Ira Pastans Molecular Biology Lab at the NIH/NCI in Bethesda, USA focused on antibody stabilization and engineering technologies, and on generating recombinant immunotoxins for cancer therapy. Dr. Brinkmann is author of numerous publications and inventor of many patents covering recombinant antibodies, pharmaco- & functional genomics, immunotoxins and protein engineering technologies and applications.

• Engineering Conjugates

Professor Brockwell is an academic in the School of Molecular and Cellular Biology and a member of the Astbury Centre at the University of Leeds in the UK. He undertook his undergraduate studies (Pharmacy) and PhD at the University of Manchester, before joining Leeds first as post-doctoral researcher and then as a Faculty member. Current research focusses on understanding the effects of force on protein structure and function and the aggregation of therapeutic and disease-causing proteins.

• Optimisation & Developability

Adam Brown is an Associate Professor of Biopharmaceutical Engineering at the University of Sheffield. He is also a co-founder and CTO of SynGenSys.

• Using Data Science to Maximise Protein Production

Alexander Buettner obtained his Ph.D. from TUM in 2016, focusing on enhancing E. coli antibody fragment expression systems at Boehringer Ingelheim Vienna. He began his professional journey at Roche as a Postdoctoral Researcher in 2016, contributing to glycan structure function studies for Neorecormon and Mircera. Over the years, he has progressed to the roles of Scientist (2017), Group Leader (2019), and Senior Scientist (2021), where he has been involved in various areas including routine (extended) characterization of biopharmaceuticals, Data Science topics, IT system validation, instrument qualification, method validation, and automation of sample preparation.

• Analytical Characterisation of Biotherapeutics

Nicola obtained a First Class degree in Applied Biochemical Sciences from the University of Ulster in 1997, then worked as a molecular biologist for SmithKline Beecham. She received her Ph.D. in Molecular Microbiology at the University of Nottingham in 2001 and moved back to industry to work on high-throughput cloning and validation of therapeutic cancer antigens for Oxford Glycosciences and subsequently Celltech R&D. Nicola then worked at the University of Oxford for 17 years, building and leading the Biotechnology Group at the Structural Genomics Consortium (SGC) and more recently, as an Associate Professor, and Head of the Protein Production Small Research Facility (SRF) in the Centre for Medicines Discovery (CMD). From September 2021, she led the Enzymology and Protein Engineering Team at Exact Sciences Innovation in Oxford, producing proteins for cancer diagnostic research. Since January 2024, she has rejoined the SGC, working as a consultant (Chief Operating Officer, Protein Sciences) coordinating protein production across the 6 SGC sites, in addition to building a membrane protein lab as a visiting scientist at UCL in London.

• Protein Process Development
• Using Data Science to Maximise Protein Production

Prof. Dr. Johannes Buyel is a biotechnologist and bioprocess engineer and by training and received his Bachelor of Science from the RWTH Aachen University in Aachen (one of Germany´s Excellence Universities) in 2006. He continued his master studies in Molecular Biotechnology with stays abroad in Sweden (Lund University, ERASMUS schoolarship) and the USA (Fraunhofer Center for Molecular Biotechnology, Newark, Delaware). Finishing his Masters with honours in 2009 he was awarded the Springoroum Coin. Johannes conducted his PhD at RWTH Aachen University during which he was a visiting scientist at the Rensselaer Polytechnic Institute (Troy, NY, USA) and Karlsruhe Institute of Technology (KIT) (Germany) for several months. He received his PhD with honours and was awarded the Borchers Medal. In 2014 he joined Fraunhofer IME as a group leader and became head of the Bioprocess Engineering department the year after. In parallel, Johannes started a second PhD in Bioprocess Engineering at the KIT, which he finished in 2017. Between 2018 and 2020 he conducted his habilitation and was an Associate Professor at the RWTH between 2020 and 2023. Johannes is an active member of the German Biotechnology Association (DECHEMA), and member of the Editorial Boards of Frontiers in Bioengineering and Biotechnology, Frontiers in Plant Science as well as Transgenic Research, where he is Editor-in-Chief since 2021. In 2022, he joined the University of Natural Resources and Life Sciences, Vienna (BOKU) as a Full Professor for Downstream Processing. Johannes has 15+ years of experience in the development of tailor-made upstream production and downstream processing for 50+ recombinant proteins, small molecules and DNA in different expression systems such as E. coli, yeast, plant cell cultures and whole plants both under GMP and non-GMP conditions. He is also focussing on integrated processing, i.e. the use of residual biomass for cascading use. Johannes was/is involved in international projects like PHARMAPLANT, FUTURE-PHARMA and RESILIANCE. Amongst others, he received a €2.5 million Fraunhofer Attract grant for a project to establish a model-driven high-throughput expression and purification platform for recombinant proteins (FAST-PEP). Johannes was a principal investigator (PI) in the tumor-targeted drug delivery graduate school of the German Research Foundation (DFG; 2018-2022) as well as the International Center for Networked Adaptive Production (ICNAP; 2016-2022) for which he has so far received funding of €0.9 million and €1.8 million respectively. His work is strongly inter- and cross-disciplinary, combining research in, for example, biotechnology, bioprocess engineering, informatics, mathematics, data science, oncology, cosmetics and nutrition. He has currently more than 80 publications (h-index 27, i10-index 51, 2333 citations as of August 2023).

• Optimising Expression Platforms

Sofia Baptista Carvalho is a senior researcher at the Animal Cell Technology Unit of iBET’s Health & Pharma Division since 2018. Sofia B. Carvalho finished her graduation and MSc in Biochemistry in 2009 and 2011 (FCUL), respectively, and in 2018 finished her PhD in Biotechnology from ITQB-NOVA. Sofia’s PhD research was in the area of Downstream processing strategies for Influenza VLPs as universal vaccine candidates as well as the development of analytical tools for process optimization and product characterization. She did part of her PhD studies at the Max Planck Institute for the Dynamics of Complex Technical Systems, Downstream Processing Lab (Germany), and at PALL Life Sciences (United Kingdom). In January 2018 she joined Genibet Biopharmaceuticals, a cGMP biopharmaceutical, to work as Project Manager of projects on viral process development and cGMP manufacturing. Later in 2018 she returned to the Animal Cell Technology Unit @iBET first as a research associate, and in 2019 as a senior researcher. Sofia B. Carvalho's research interests are related to downstream processing and analytical tools of biopharmaceuticals, covering protein expression and purification, virus and VLP production (from cell expansion to product purification), Impact of operating variables on process performance and product quality, and the development of analytical tools for bioprocess understanding and biologics characterization (quantitative and qualitative). She participated as a team member in several publicly funded research projects (FCT and EC) and operates as a project manager in research services with the biopharmaceutical industry. Sofia B. Carvalho authored 18 manuscripts, 1 conference paper, and 1 book chapter, receiving a total of 435 citations (h-index 12). During her PhD, she tutored 2 MSc students (2 theses defended). Sofia B. Carvalho received 2 awards and 8 grants and participated as author/co-author of more than 20 oral presentations and 30 poster communications.

• Protein Process Development

I completed my PhD in Biophysics and Biochemistry at The Francis Crick Institute and received my PhD award from UCL. During this time I investigated the enzymatic activity of proteins involved in HIV-1 restriction and subsequently DNA damage repair. As an Associate Principal Scientist at AstraZeneca, I specialise in protein science, production, and biophysical characterisation of proteins and project management within early drug discovery.

• Using Data Science to Maximise Protein Production

Samuele Cazzamalli (Italian, 16 December 1990) studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zu¨rich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for applications in oncology. Samuele works now at Philochem AG (Switzerland), where he heads the “Small Molecule Therapeutics” team, a research unit that focuses on the development of products based on small organic ligands for tumor-targeting applications.

• Engineering Antibodies & Beyond

I did my Ph.D. at Bioprocess and Cell Engineering Group at Universitat Autònoma de Barcelona where I developed a project in the field of bioengineering devoted to the production of HIV-1 Virus-like particles as a platform for recombinant vaccine production. I combined my research with undergraduate teaching at UAB. After finishing my PhD, I enrolled as Postdoctoral Fellow at the Bioengineering Department at McGill University (Montreal, Canada), under the supervision of Prof. Amine Kamen. My research focused on the development of a production process for Influenza VLPs using the Baculovirus/Insect cell platform. Nowadays I have a position at UAB as a postdoctoral fellow working on the development of a bioprocess to produce Adeno-Associated vectors for gene therapy.

• Protein Process Development

Ross Chambers is the Vice President of Antibody Discovery at Integral Molecular. He pioneered the use of DNA immunization for antibody production and developed Integral Molecular’s MPS system for isolating antibodies. Dr. Chambers earned his PhD from the University of Otago, New Zealand, and did post-doctoral studies at UC Davis and Berkeley. Before joining Integral Molecular, he was the Director of R&D at SDIX and directed the discovery of thousands of commercial antibodies.

• SC5: Best Practices for Targeting GPCRs, Ion Channels, and Transporters with Monoclonal Antibodies

Javier joined Pfizer in 2007, and is leading the BioTherapeutic Discovery department within Biomedicine Design. He is responsible for leading biotherapeutic discovery work, including lead generation and optimization, biophysical characterization, and non-GLP biotherapeutic production. During his tenure at Pfizer he worked on conventional/bispecific/trispecific antibodies, antibody-cytokine fusions, antibody drug conjugates, CAR T cells, oncolytic viruses, and mRNA therapies. Javier is interested in understanding the underlying biology of drug design and delivery and engineering solutions for challenges associated with developing the next generation of biotherapeutics.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Henry Chiou is Senior Director and General Manager for the Delivery and Protein Expression business within Biosciences at Thermo Fisher Scientific. He and his teams have developed products such as the Expi family of 293, CHO and Sf9-based expression systems, Lipofectamine 3000, and other Lipofectamine-family transfection reagents, production systems for cell and gene therapy viral vectors such as AAV MAX system. Henry has authored multiple publications on mammalian transient expression and frequently teaches courses and lectures on this subject. Prior to joining Thermo Fisher, Henry worked in small to mid-sized biotech companies on non-viral gene therapy. Henry received his doctorate from Harvard University in Molecular Pharmacology, following which he completed a postdoctoral fellowship in viral expression systems at the University of Pennsylvania.

• TS9A: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology

Affilogic is a privately-owned biotech company specialized in discovery and development of a novel class of protein therapeutics called Nanofitins. Since joining Affilogic in 2011, Dr. Mathieu Cinier successfully led 60+ Nanofitin generation programs for a wide range of applications, and Nanofitin-based biotherapeutics are currently being developed in collaboration with Sanofi, Takeda Pharmaceutical and other undisclosed international pharmaceutical companies. He also applied its extensive protein engineering knowledge to expand the potential of the Nanofitin technology and is now assuming the position of Scientific Director.

• Emerging Targets and Therapeutic Approaches

Charlotte Coles is a Team Leader at GSK, based in the Large Molecule Discovery department at the Stevenage (UK) R&D site. She leads a group focused on developing platform processes and workflows to support early-stage (pre-CMC) discovery campaigns for projects using multispecific antibody formats. Charlotte’s main background expertise is in structural and molecular biology, with prior industrial experience using structure-guided approaches to aid large molecule therapeutic design and optimisation.

• Advancing Multispecifics and Combination Therapy to the Clinic

Chris joined CHARM Therapeutics, an AI-driven biotech company as Director and Head of Protein Sciences in 2022. CHARM’s research focuses on novel approaches for cancer drug discovery using protein and ligand co-folding algorithms for hard-to-drug targets. Prior to this, Chris was the Director of Protein Science at Peak Proteins, but for most of his career he studied the biochemistry and structural molecular biology of DNA repair and replication. He was a Senior Lecturer in Biological Sciences at the University of Huddersfield for 6 years and performed his postdoctoral research at the University of Oxford, working at the Structural Genomics Consortium and Sir William Dunn School of Pathology. During this period Chris was also a College Lecturer in Biochemistry at The Queen’s College, and a Junior Research Fellow at Linacre College.

• Using Data Science to Maximise Protein Production

Dr. Christopher Corbeil is a research officer at the National Research Council Canada (NRC) who specializes in the development and application of computational tools for biotherapeutic design and optimization. He is also an associate member of the McGill Biochemistry Department and teaches classes in Structure-Based Drug Design at McGill University. After receiving his PhD from McGill University, he joined the NRC as a Research Associate investigating the basics of protein-binding affinity. Following his time at the NRC he joined Chemical Computing Group as a research scientist developing tools for protein design, structure prediction, and binding affinity prediction. He then decided to leave private industry and rejoin NRC with a focus on antibody engineering. Dr. Corbeil has authored over 30 scientific articles and is the main developer of multiple software programs.

• TS7A: Introduction to Machine Learning for Biologics Design

Dr. José Luis Corchero graduated in Biological Sciences (Universidad de Barcelona, 1990), and later obtained a Master Degree in Biotechnology (UB, 1993), and a PhD in Biological Sciences (UAB, 1997) in the fields of recombinant protein production, and protein folding and aggregation. He performed a post-doctoral stay (1998-2000) at the “Centers for Disease Control and Prevention” (CDC, Atlanta, USA), working in the field of development of diagnostic kits for herpes viruses. In November 2000, he incorporated to the R+D section of the company Biokit SA, where he continued to work (2000-2007) in the field of development of diagnostic kits. Since 2007, Dr. Corchero has been a senior researcher at the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Dr. Corchero's current research mainly deals with the production of recombinant human proteins in mammalian cells as expression system, for their use as therapeutics in the treatment of Fabry disease, and of protein-based nanoparticles as drug delivery systems.

• Protein Process Development

Tom Cornell gained his Ph.D from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Tom has gained a wealth of protein engineering experience. At Abzena, Tom works within the protein engineering department working on pre-clinical development of Antibody drug candidates.

• Optimisation & Developability

Rebecca is an innovative leader responsible for the implementation of novel and disruptive in silico technologies to increase the speed of discovery and quality of biologics therapeutics. She is an experienced antibody engineer with structural biology expertise and was co-inventor of the CrossMab technology that is now leading the way in approvals for multi-specific antibody therapeutics. She has authored 30+ patents and publications in the field of antibody engineering.

• Display of Biologics

Tim Dafforn is professor of Biotechnology at the University of Birmingham. He pioneered the use of Styrene Maleic Acid Lipid Particles (SMALPs) for the production of membrane proteins. He has a strong record in collaborating with industry on drug discovery projects. Professor Dafforn also has expertise the development of Process Analytical Technology solutions for downstream bioprocess monitoring.

• Antibodies Against Membrane Protein Targets

Dr. Rony Dahan is a senior scientist (assistant professor) at the Department of Systems Immunology of the Weizmann Institute of Science. He is the incumbent of the Rina Gudinski Career Development Chair.

• Engineering the Next Generation of Bispecific Antibodies

Bassil I. Dahiyat, Ph.D. has served as a member of our board of directors since June 2018 and as a member of our compensation committee and audit committee since September 2018. Dr. Dahiyat has served as President and Chief Executive Officer of Xencor, Inc., a biopharmaceutical company, since February 2005. Dr. Dahiyat co- founded Xencor in 1997, served as its Chief Executive Officer from 1997 to 2003 and served as its Chief Scientific Officer from 2003 to 2005. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat currently serves on Xencor’s board of directors. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University.

• Advancing Multispecifics and Combination Therapy to the Clinic

Dr. Foram Dave earned her PhD from Plymouth University in 2019, focusing on targeted drug therapy for NF2-related nervous system tumors. Since 2021, she has applied her expertise as a Research Scientist at Scancell, specializing in in-house antibody functional characterization. Her work bridges academia and industry, advancing cancer immunotherapy with a focus on innovative therapeutic strategies.

• Next-Generation Immunotherapies

Following a degree in Biology at the University of Padua, Carmela joined Professor Vincenzo Bronte’s group in 2002 to study for a PhD. Her studies focussed on myeloid derived suppressor cells (MDSCs), a heterogeneous grouping of myeloid lineage cells that suppress immune responses, and which are emerging as a key immunoregulatory axis, both in the context of pathogen-specific immunity, and also tumour-specific immune responses. After successfully completing her PhD, she carried out post-doctoral studies in Professor Vincenzo Cerundolo’s laboratory in the Weatherall Institute for Molecular Medicine in Oxford, in 2006, where her research again focussed on MDSCs both in cancer and virus infection, and also investigated the ability of invariant Natural Killer T cells to regulate MDSCs suppressive activity.

• Innovative CAR T Therapy

Charlotte is Professor of Structural Bioinformatics in the Department of Statistics at the University of Oxford and co-director of the Systems Approaches to Biomedical Research Centre for Doctoral Training which she founded in 2009. In January 2024, Charlotte became Executive Chair of the Engineering and Physical Sciences Research Council (EPSRC). From 2022 to 2023, Charlotte was Chief AI Officer at Exscientia, a biotech with ~450 employees, where she led its computational scientific development. She has held numerous senior roles at the University of Oxford including Head of the Department of Statistics and Deputy Head of the Mathematical, Physical and Life Sciences (MPLS) division. She was the Deputy Executive Chair of the UK’s Engineering and Physical Sciences Research Council from 2019 to 2021. She served on SAGE, the UK Government’s Scientific Advisory Group for Emergencies, during the COVID-19 pandemic, and acted as UK Research and Innovation’s COVID-19 Response Director. She was appointed Member of the Order of the British Empire (MBE) in the 2022 Birthday Honours for services to COVID-19 research. At Oxford, Charlotte leads the Oxford Protein Informatics Group (OPIG), who work on diverse problems across immunoinformatics, protein structure and small molecule drug discovery; using statistics, AI and computation to generate biological and medical insight. Her work focuses on the development of novel algorithms, tools and databases that are openly available to the community. These tools are widely used web resources and are also part of several Pharma drug discovery pipelines. Charlotte is on several advisory boards and has consulted extensively with industry. She has set up a consulting arm within her own research group as a way of promoting industrial interaction and use of the group’s software tools.

• Display of Biologics
• Optimisation & Developability

Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator at Imperial College in Antibody Technology, which led to some novel technologies being developed commercially. Dr Deonarain now retains an honorary position. He has published over 80 papers and patents in protein/antibody engineering/conjugates. In 2014, he co-founded Antikor Biopharma where he is the CEO leading a team to develop the next-generation of antibody-fragment based ADCs

• Engineering Conjugates

A biochemist by training, Achim has been designing and progressing bispecific antibodies and bispecific ADCs preclinically for over a decade, including technology development for their effective screening. Complementary interests are protein engineering and optimized screening of complex biotherapeutics via mammalian libraries in microfluidic functional screens.

• Protein Process Development

My current research in the field of bio/cheminformatics and data science can be summarized as developing novel computational methods for biomolecular sequence analysis, protein function prediction and computational drug discovery; using statistical learning, data mining and (deep) machine learning techniques and graph theory approaches. As an interdisciplinary researcher, I always try to approach biological problems from different angles, using the fundamentals and techniques generally applied in other relevant disciplines, to be able to propose novel and effective solutions to prevalent issues. My overall research philosophy is to utilize the knowledge obtained by valuable and hard-to-conduct wet-lab experiments to accurately model the biological systems in-silico, with the aim of assisting the ongoing work in biomedical research. For this, I divide my work in 3 major parts: (i) integrating complementary biological data from various open access data repositories in order to generate a bigger picture using the current bio-knowledge; (ii) developing novel in-silico methods and applying on large-scale biological data in order to estimate/predict what has been missing from the current knowledge; and (iii) further analysing the specific parts of the produced well-annotated biological data (enriched/completed with the in-silico predictions) to infer biological insight. I give emphasis on publishing the produced data via open-access data repositories where the whole research community can work on it to further our biological understanding on different subjects.

• Machine Learning Approaches for Protein Engineering: Part 2

Since obtaining a BSc in Biochemistry from the University of Manchester, Jen has worked for over 20 years with antibody-based formats within GSK. Initially working on expression and purification of antibody-based molecules, then moving focus to biophysical analytical techniques including differential scanning calorimetry (DSC) and dynamic light scattering (DLS). Jen leads the team that developed and embedded the panel of in vitro assays to assess in vivo suitability of lead panels of antibody candidates within GSK.

• Optimisation & Developability

Cyrille Dreyfus is a Protein Biochemist who has more than 10 years of combined industry and academic experience in large molecule drug discovery. He holds a PhD in Protein Engineering and Structural Biology from the CEA (French Alternative Energies and Atomic Energy Commission). In 2010, Cyrille worked for 2 years on broadly neutralizing antibodies against influenza viruses at the Scripps Research Institute in the research group of Professor Ian Wilson. In 2013, he joined the Center of Immunology Pierre Fabre as a Senior Scientist working on monoclonal antibodies against key therapeutic targets in oncology. At present, Cyrille is heading the Protein Sciences group in the Antibody Discovery and Engineering Department at Ichnos Sciences (Lausanne, Switzerland). His work focuses on the preclinical development of novel multi-specific cancer immunotherapies based on immune cell engagers such as ISB 1442, a CD38xCD47 macrophage engager, and ISB 2001, a BCMAxCD38xCD3 T cell engager.

• Optimisation & Developability

Mike Dyson is Senior Director at Ichnos Sciences responsible for the antibody discovery, optimization, screening, and characterization leading to the development of novel bi- or tri- specific immune engager therapeutics for cancer immunotherapy. He was Chief Technology Officer and co-founder at IONTAS Ltd., a therapeutic antibody discovery company where he either directly project managed or oversaw 56 antibody discovery and development projects partnered with 30 companies including 5 top 20 Pharmas. This included the development of 8 biologics (antibody or bi-specific format) to commence human clinical trials or approaching IND filing to treat auto-immune disease or cancer. Mike was previously Head of Protein Engineering at Acambis plc (acquired by Sanofi) and Project Leader at the Wellcome Trust Sanger Institute. He holds a PhD in organic synthetic chemistry from the University of Birmingham and post-docs at MIT and the Universities of Edinburgh and Cambridge. He has published 40 papers and book chapters (cited over 1800 times) and is inventor on 16 US patent and patent applications mainly focused on novel antibody therapeutics.

• Display of Biologics

Takashi is COO of GeneFrontier Corporation (GFC) since 2010. Takashi got his PhD for the research of cell-free protein expression system at Tokyo Institute of Technology in 2000 and joined in VC in life science industry. At 2003, Takashi was involved in establishing of GFC and fully committed to business development of GFC from the beginning.

• Optimising Expression Platforms

Peter Ellmark, PhD, is Chief Scientific Officer at Alligator Bioscience and holds an associate professorship in Immunotechnology at Lund University. Dr. Ellmark has more than 20 years’ experience of developing antibodies for immunotherapy of cancer and has a strong track record of developing mono- and bispecific antibodies for tumor-directed immunotherapy of cancer, focusing on the co-stimulatory checkpoint receptors CD40 and 4-1BB.

• Advancing Multispecifics and Combination Therapy to the Clinic

M. Frank Erasmus is the head of bioinformatics at Specifica, Inc. where he specializes in the use of next-generation sequencing technologies and software development to aid in the design of and selection from therapeutic antibody libraries. Formerly, Frank was awarded a national fellowship from the National Cancer Institute for his translational research associated with B cell precursor acute lymphoblastic leukemia conducted at the Spatiotemporal Modeling Center and Los Alamos National Labs. He brings over 13 years of experience in both biotechnology and academic settings in the development and characterization of therapeutic antibodies using theoretical modeling, bioinformatics, and experimental approaches.

• Machine Learning Approaches for Protein Engineering: Part 2

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) and Project Lead for the RAS Reagents Core at the Frederick National Laboratory for Cancer Research in Frederick, Maryland. The 38 employees in the PEL clone, express, and purify proteins from a variety of host organisms in support of the NCI RAS Initiative and for investigators at the National Institutes of Health. In addition, the PEL invents and develops novel technologies for improving protein expression and production, focused heavily on baculovirus expression technology and combinatorial cloning. Prior to his role as director, Dr. Esposito led the Clone Optimization Group in the PEL for nine years and was responsible for the generation of over 15,000 expression clones, 400 new expression vectors, and several technological innovations in protein expression. Dr. Esposito received his B.A. in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry in the laboratory of Dr. John Scocca at the Johns Hopkins University Bloomberg School where he studied bacteriophage site-specific recombination. Dr. Esposito then worked as a postdoctoral fellow in the laboratory of Dr. Robert Craigie at the NIDDK, where he studied the protein-DNA interactions involved in the HIV integration reaction. Prior to joining the FNL in 2001, Dr. Esposito worked for three years as a Staff Scientist in the Protein Engineering group at Life Technologies, where he helped to develop the Gateway recombinational cloning system. Dr. Esposito has published over 100 peer-reviewed manuscripts in the fields of protein expression and DNA recombination.

• TS9A: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology
• Protein Process Development

Since October, 2020, Dr. Andreas Evers has worked computer-aided assessment and optimization on NBEs at Merck Healthcare KGgaA. He obtained his PhD in Computational Chemistry with Professor Gerhard Klebe at Philipps University of Marburg in 2000. He joined Sanofi in 2003, first working in the area of computer-aided drug design on “small molecule” projects and later on therapeutic peptides and proteins. His research activities include implementation and application of in silico and AI approaches to design new molecules with the desired target activity and developability properties.

• Display of Biologics
• Optimisation & Developability

Dr. Marina Fedorova is a scientific investigator at GSK who works in the Cellular Technology team (Protein and Cellular Science). A chemist by training, Marina has worked as a researcher at the MRC Immunochemistry Unit at Oxford University and MRC LMCB at University College London. After receiving her PhD in Chemical biology from Imperial College; she has carried out her scientific career at LifeArc and Orchard Therapeutics as a cell biologist and analytical scientist. She then joined GSK with a focus on cellular technology and customisable cell line generation.

• Optimising Expression Platforms

I am a chemist with a PhD in Computational Biophysics. After a short stay at Pfizer (Boston), I joined Professor Höcker's lab (Bayreuth, Germany) as a postdoc, where I worked on developing computational methods for protein design. I'm currently a Group Leader at the Institute of Molecular Biology of Barcelona. My group focuses on the implementation of generative AI methods for protein design. I believe protein design has the potential to change the world we live in, and AI is at the core of this revolution.

• Machine Learning Approaches for Protein Engineering: Part 2

Dana Filoti is Associate Director, Development Sciences Data and Digital Strategy, focusing on the Biologics CMC Data Architecture. She received her PhD in Materials Science from the University of New Hampshire and Bachelor's degree in Physics from the University of Bucharest. She joined Abbvie after working as a Post-Doctoral fellow with Genentech and the Biomolecular Interaction Technologies Center (BITC) on the development of instrumentation to measure protein charge and macromolecular interactions of proteins at high concentration. Her current research focuses on transformative data automation and nominal analysis strategies to interpolate multimodal CMC data and knowledge platforms.

• Analytical Characterisation of Biotherapeutics

Sarel Fleishman is an associate professor at the Weizmann Institute of Science, where his research team develops a computational protein-design methodology to address challenges in biochemistry and protein engineering. As a postdoc with David Baker in Seattle (2007-2011), Sarel developed the first accurate methods for designing protein binders, culminating in the design of broad-specificity influenza inhibitors. At the Weizmann Institute (2011-), his team developed protein design methods to the level of accuracy and reliability required to design large and complex proteins such as enzymes, antibodies, and vaccine immunogens - a protein that was designed in the Fleishman lab has recently been approved for mass production as a vaccine for malaria. The team recently developed a fully automated method, called PROSS, for dramatically improving the stability and expressibility of recalcitrant proteins and several design methods for improving affinity, specificity, and catalytic rates in antibodies and enzymes. Current focuses include developing methods for designing large repertoires comprising millions of enzymes or antibodies for one-shot isolation of highly active, specific, and stable binders, inhibitors, or enzymes. Among Sarel’s academic awards were the Clore Ph.D. Fellowship (2003-2006), the Science Magazine award for a young molecular biologist (2008), a postdoctoral fellowship (2006-2009) and a career-development award (2012-2015) from the Human Frontier Science Program, European Research Council Starting and Consolidator Grants (ongoing), the Alon Fellowship, the Henri Gutwirth Prize, and the Weizmann Scientific Council Award.

• Display of Biologics

Rachel Fong is the Director of Sales and Alliances at Integral Molecular, with over 10 years of experience at the company. Rachel manages relationships with customers, collaborators, and partners for MPA projects. As a founding member of the scientific team that launched this platform, she brings a unique perspective that helps guide partners from initial discussions to successful project completion. Rachel joined Integral Molecular in 2010 and is a co-author on over a dozen publications.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Dr Elisa Fontana, MD, PhD is the Hospital Medical Director of the Sarah Cannon Research Institute in London, UK (part of HCA International and ESMO Designated Centre of Oncology and Palliative Care). She is Principal Investigator for over 20 first-in-humans to late phase clinical trials and oversees a portfolio of more than 70 active clinical trials and translational studies. She graduated from the University of Parma, Italy in 2008 and completed her specialisation in Medical Oncology in 2014. She worked as sub-investigator in the gastrointestinal and drug development clinical trial units at The Royal Marsden Hospital, UK (2014-2019). She was awarded a PhD in colorectal cancer and biomarker assays development at the University of London, Institute of Cancer Research in 2019; she received the Chairman’s Prize for outstanding PhD. She successfully completed an entrepreneurial training programme for early career researchers aiming to translate research into clinical practice. She served as co-Chair of the Adolescent and Young Adult Gastrointestinal Cancer Task Force at the European Organisation for Research and Treatment of Cancer (EORTC) (2019-2020). She is the current secretary of the EORTC Gastrointestinal Tract cancer group (2021-2024 mandate). She has received multiple academic funding as lead applicant and over 10 ESMO and ASCO Merit Awards for conference presentations; she has published over 100 peer-reviewed articles, abstracts and book chapters.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Agnete B. Fredriksen is Co-founder, President and CSO of Vaccibody AS. She joined Vaccibody as CSO in 2007, where she has been responsible for moving innovative immunotherapy from idea to clinical development with several programs in the pipeline with a major focus on infectious diseases and cancer, including cancer neoantigen vaccines. She has more than 17 years of experience from early-stage biotech and commercialization. She is an inventor on several patents. She is a board member for Enabling Technologies of NRC. Agnete received her Ph.D. from Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she was awarded with the King’s Gold Medal for her thesis.

• Emerging Targets and Therapeutic Approaches

Fredrik Frejd is the Chief Scientific Officer at Affibody and has over 25 years of experience in life science research with particular expertise in biologics drug development and tumor biology, phage display and therapeutic protein engineering of alternative scaffolds. Dr. Frejd received his Ph.D. from the Swiss Federal Institute of technology, ETH, in Zurich in 2001 and joined Affibody AB in 2002. Dr. Frejd is also an adjunct professor in cancer precision medicine at the department for Immunology, Genetics and Pathology at Uppsala University, with a special focus on development of minimized tumor targeting agents for targeted payload therapy.

• Engineering Antibodies & Beyond

Björn Frendéus is the CSO of BioInvent, a Swedish Biotech developing antibody-based treatments for cancer immunotherapy. Björn got his PhD studying innate immune responses to microbial infection. Over the past decades, he has developed a strong interest in understanding the complex biology of antibodies in relation to their targets, and applying his knowledge to develop better antibody-based medicines. Björn’s team conceived and developed the F.I.R.S.T platform from which BioInvent’s current pipeline has emerged. This includes the Company’s proprietary clinical-stage anti-FcgRIIB (BI-1206 and BI-1607) and anti-TNFR2 programs (BI-1808), BT-001 - a clinical-stage oncovirally encoded Treg depleting anti-CTLA-4 antibody co-developed with French vaccine company Transgene, and F.I.R.S.T TAM that BioInvent recently partnered with Pfizer on to develop novel antibodies and targets to tumor-associated myeloid cells with the aim to overcome resistance in the tumor microenvironment. BioInvent is closely collaborating on several of its programs with the Cancer Sciences Division in Southampton, UK, where Björn is a visiting professor. Björn chairs the Swedish Foundation for Strategic Research (SSF)’s expert review committee on Infection Biology.

• Next-Generation Immunotherapies

Per-Ola Freskgård is Vice President Science & Technology at BioArctic AB and a member of the Research & Development Leadership Team. Per-Ola previously served as Vice Director & Distinguished Scientist within the Roche Neuroscience Discovery organization in Switzerland, responsible for preclinical development of the Brain Shuttle delivery technology of biologics, which is now in clinical testing. Prior to that, he held a Section Head position in early and late discovery at AstraZeneca within the Neuroscience area and was a member of the Technology Research Review Committee within the Medimmune and AstraZeneca organizations. Before joining AstraZeneca, Per-Ola served as Vice President and a member of the Executive Management Team at Nuevolution A/S and a co-inventor of the Chemetics technology. Prior to this, Per-Ola was a Project Manager at Maxygen responsible for research programs of antibody mimetics and a co-inventor of the Maxybody concept. Prior to that, Per-Ola was Head of the Discovery Research Department in the therapeutics division at Novo Nordisk A/S. Per-Ola conducted his post-doctoral fellowship in Professor Frances Arnold’s lab at the California Institute of Technology. He holds a PhD in Protein Biochemistry from Linköping University, Sweden. He authored and co-authored more than 80 peer-reviewed publications and patent applications.

• Engineering Antibodies & Beyond

Nathan is a Senior Machine Learning Scientist and Group Leader at Prescient Design, Genentech. At Prescient, his group develops and applies machine learning methods to molecular discovery and design. Previously, Nathan was a Postdoctoral Associate at MIT working with the Lincoln Lab Supercomputing and AI groups. He was a National Defense Science & Engineering Graduate Fellow at the University of Pennsylvania, where he obtained his PhD in Materials Science & Engineering. During graduate school, Nathan was an affiliate scientist with the Materials Project at Berkeley Lab.

• Machine Learning Approaches for Protein Engineering: Part 1

Simone holds a degree in Biotechnology from the WWU Münster and completed her PhD studies at the Institut for Clinical Neuroimmunology at the LMU Munich studying the role of expanded antibody species in mutliple scleorsis patients before joining iOmx in 2016. She held different technical roles at iOmx with focus on protein science throughout her tenure at iOmx and is responsible for generation and technical advancement of binders to iOmx proprietary targets in her current function as Head of Antibody Discovery and Development.

• Emerging Targets and Therapeutic Approaches

Jeremy gained his DPhil under the supervision of Prof. Kathryn Wood from the University of Oxford developing gene therapy strategies to induce immunological tolerance in transplant recipients. Jeremy joined ProImmune in 2001 to generate a new class of MHC multimer staining reagents. For more than 20 years as ProImmune's Director of Sales, he has led the sales team in a growing business, focusing on developing and implementing innovative technologies that radically improve our understanding of immune responses.

• Display of Biologics

After completing a Master’s Degree in biology and chemistry, I pursued my PhD at the University of Montpellier, where I developed an antibody screening tool combining bacterial production and click chemistry. In 2017, I joined UCB and have led successful antibody discovery and engineering campaigns against multiple target classes using both B cell cultures and display technologies. More recently, my focus has shifted towards using naïve phage and yeast display libraries, as well as exploring alternative antibody repertoires, including llamas and cows.

• Display of Biologics

I am the Chief Scientific Officer at EpiBiologics. I bring over 20 years of experience as an executive manager leading innovative discovery research groups focused on turning novel ideas into clinical stage therapies to battle cancer, autoimmune, and neurodegenerative diseases. During my time at Elan Pharmaceuticals and Seagen, I headed the discovery and delivery of over 6 phase 1 clinical candidates that integrated novel antibody, chemistry, and protein engineering technologies. Most recently I was the Vice President of Therapeutic Discovery Research at Seagen where she led a 60+ member team comprised of chemists, protein engineers, immunologist and cancer biologist focused on discovering new treatments for cancer patients. I trained as an Immunologist at the University of Colorado and went on to complete a postdoctoral research fellowship in the Department of Immunology at National Jewish Health.

• Engineering Antibodies & Beyond

Elena Garralda, MD, MSc, is a medical oncologist, researcher, and clinical investigator. Currently the Director of the Early Drug Development Unit at VHIO, the Co-Director of VHIO’s Clinical Research Program, and the Director of the Phase I Unit at NEXT Oncology, in Barcelona she is also member of several Scientific Committees and European Consortia. She obtained her Medical Doctor degree from the Universidad Autónoma, Madrid, in 2005. Spent one year as head coordinator of a medical health center in Battambang, Cambodia, and came back to specialize in Medical Oncology at Hospital 12 de Octubre, Madrid, earning her license in May 2011 on position #12 of MIR examination that year. She then accomplished the Advanced Studies Diploma (D.E.A.) at the Universidad Complutense, Madrid, as part of her PhD degree, a 2-year Master’s degree in Molecular Oncology at the Spanish National Cancer Research Centre (CNIO), and a Master’s degree in Management Skills for Scientists and Researchers at IE Business School; both with the highest recommendation. Early drug development has always been a major interest, especially translational oncology, targeted therapies, and personalized cancer medicine. Very involved with the research at the Gastrointestinal Cancer Clinical Research Unit in CNIO and in the South Texas Accelerated Research Therapeutics (START) Centers in her early years, she was later recruited to lead the Early Drug Development Unit at VHIO, Barcelona, where she is the Principal Investigator and the Director since 2017. There she coordinates the phase I program and the clinical research program, where complex clinical trials with drugs in early development (phase I and early phase II trials) focus in novel targets. In 2021, she was proposed as Director of NEXT Oncology Therapeutics subsidiary in Barcelona. Both units are mainly focused on proof-of-concept and proof-of-mechanism trials with targeted therapies, with special emphasis on those in cell signaling, cancer stem cells, immuno-oncology, and first-in-human studies of targeted therapies, rational combinations of targeted therapies, biomarker-driven trials, and trials in molecularly selected populations.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Melissa is the Vice President of Drug Discovery at Diagonal Therapeutics. She has over 15 years of industry experience in the discovery and development of innovative antibody drugs. Melissa has also worked at Biogen, Kiniksa Pharmaceuticals, and Merrimack Pharmaceuticals in their early discovery groups. She was a postdoctoral fellow at the Whitehead Institute and received her PhD in Biochemistry from Emory University.

• Advancing Multispecifics and Combination Therapy to the Clinic

Dr. Geierstanger is an experienced scientific leader with a demonstrated history of strong leadership, creativity and accomplishments in the biotechnology industry. He is skilled in guiding and motivating diverse and interdisciplinary teams engaged in drug discovery and platform & technology development. He has a passion to improve the lives of patients.

• Engineering the Next Generation of Bispecific Antibodies

Nimish Gera is the Vice President of Biologics at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over fifteen years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology, and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.

• Engineering Conjugates
• SC1: Developability of Bispecific Antibodies: Formats and Applications

Dr. Ghayur retired from AbbVie (July 2021) and works as an independent consultant. He has 30+ years’ experience leading multi-disciplinary and cross-therapeutic area Biologics discovery programs and developing novel Biologics platforms. Several biologics programs resulted in clinical development candidates. Dr. Ghayur led the team that pioneered the discovery and development of the Dual - variable - Domain -Ig (DVD-Ig) and other multi-specific platforms. Dr. Ghayur also led the team that defined the uptake, intracellular trafficking, and lysosomal degradation of anti-TNF mAbs/DVD-Ig, resulting in the concept of anti-TNF-ADC (next-Gen anti-TNF). In addition, Dr. Ghayur proposed and helped implement several corporate-wide (Abbott & AbbVie) initiatives to foster cross-functional/cross-TA collaborations to bring forward innovative concepts/programs.

• Advancing Multispecifics and Combination Therapy to the Clinic

I did my Master’s in Medical Biotechnology in Milan before undertaking a one-year internship at Texas Children’s hospital to learn about CAR T cell technologies. On returning to Italy, I pursued a PhD in Immunology. I undertook my postdoctoral studies in Switzerland, in genomics and epigenetics, after which I took up my position as Research associate within the Hi-TIDe.

• Innovative CAR T Therapy

Structural biologist and protein engineer by training with 11 years of experience in small molecule and biologics drug discovery within large pharmaceutical company and biotech. Having completed my PhD at the Biozentrum, University of Basel, I moved to the Novartis Institutes for Biomedical Research as a Postdoctoral fellow to decipher the structural basis of the IL-17 cytokine signaling and contribute to the development of small molecules and biologics to block its pathway. I then moved to the Biotech sector, first at Galapagos, where I applied structure-based approaches for the design of small molecule drugs targeting autoimmune and inflammatory diseases, and then, at Ichnos Glenmark Innovation where I contributed to the discovery of bispecific antibodies for cancer immunotherapy. Since March 2022, I am heading the Protein Sciences team at Bright Peak Therapeutics with a mission to engineer novel cytokine and immunocytokine therapies for the treatment of cancer and autoimmune diseases.

• Next-Generation Immunotherapies

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in Berlin and MRC in Cambridge, SG founded, lead and matured Biotech companies successfully as CEO and CSO over 17 years before joining DTU as professor, Deputy Head of the Department and Head of Innovation & Entrepreneurship. Extensive experience in Strategic & Corporate Development, Investor Financing & Licensing, R&D, patenting and GMP manufacturing, incl. Early Research & Discovery, Preclinical Development, Process Development, Toxicology of Biopharmaceuticals, and Clinical Development and from FIM to larger PhIIb Studies. Heading R&D of biotherapeutic antibodies and proteins, complex antibody engineering, phage display, cellular and molecular glycoengineering, mammalian production cell system engineering, USP and DSP production process development. Heading GMP-production, preclinical and clinical development.

• Advancing Multispecifics and Combination Therapy to the Clinic

Patrícia Gomes-Alves has been a lab head at the Animal Cell Technology Unit of iBET’s Health & Pharma Division since 2018. In 2009, P Gomes-Alves finished her PhD in Biology from ITQB-NOVA, in collaboration with the Instituto Nacional de Saúde's Dr. Ricardo Jorge, developing research in the area of proteomics/mass spectrometry tools and biomarker discovery in cystic fibrosis. She did part of her PhD studies at C Boyd’s Lab, Western General Hospital, University of Edinburgh (UK), and JP Albar’s Lab, Universidad Autónoma de Madrid (Spain). In May 2010, she joined a biotechnology SME, TheraProteins, to work as Director of Development, being in charge of the development of biotechnological products, namely oligosaccharide reference standards. In 2011, she joined the Animal Cell Technology Unit @iBET as a Senior Scientist at the Cell Bioprocesses Lab, and in 2013, took over the scientific coordination of the Mass Spectrometry Unit (UniMS) at iBET/ITQB-NOVA. In 2018, became a lab head at the Animal Cell Technology Unit@iBET. Dr. Gomes-Alves's research interests cover the areas of bioprocessing, -omics tools, and mass spectrometry (MS). Her projects have focused on the development and implementation of MS-based workflows to characterize and streamline bioprocesses and resulting cell products. Dr. Gomes-Alves authored 53 manuscripts and 2 book chapters, receiving a total of 825 citations (h-index 15), was also responsible for the supervision of 2 PhD students (theses defended in 2018 and 2022), 5 MSc students, and participated in several publicly funded research projects (FCT and EC), and coordinated several R&D projects with the biopharma industry.

• Optimising Expression Platforms

Immunologist with extensive experience in Autoimmune and Inflammatory Disorders, Dr. Gonzalo-Gil supports JAX Preclinical services to characterize mouse models for Autoimmunity and Rare Diseases, and to offer support to Academics and Pharma Biotech to evaluate the in vivo stability and efficacy of new therapeutic antibodies using JAX FcRn mouse models

• Emerging Targets and Therapeutic Approaches

Amy Gorman is a final year PhD student at the University of Manchester, researching the behaviour of lipopolysaccharide in biopharmaceutical formulations. Her research interests include developing novel fluorination methodologies and utilising 19F NMR and light scattering techniques to investigate aggregation behaviour in formulations.

• Protein Stability & Formulation

I studied pharmacy at the LMU in Munich, followed by getting into the biotech world of Amgen. After two years at the process development department, I took the opportunity to get deeper insight through research on my doctoral thesis in the cellular sciences team there.

• Optimising Expression Platforms

Peyton Greenside is the co-founder and CSO of BigHat Biosciences, an early-stage Bay Area startup developing an AI-first experimental platform to radically reduce the difficulty of designing antibodies and other therapeutic proteins. Before BigHat, Peyton was an inaugural Schmidt Science Fellow, a computational biologist at the Broad Institute, a scientific founder of Valis, and holds a PhD from Stanford University, an MPhil in Computational Biology from Cambridge University, and a BA in Applied Math from Harvard.

• Optimisation & Developability

Dr. Victor Greiff is Associate Professor for Computational and Systems Immunology at the University of Oslo. His work focuses specifically on the development of machine learning, computational and experimental tools for the analysis, prediction and engineering of adaptive immune receptor repertoires.

• Machine Learning Approaches for Protein Engineering: Part 2

No bio available.

• Machine Learning Approaches for Protein Engineering: Part 1

Maria is an industry recognized expert and leader in antibody display technologies and protein engineering and has >20 years of experience in this field. Maria has worked in Academia, Biotech and Biopharmaceutical roles and has diverse knowledge base which spans from molecular biology through to large scale protein production. As a project leader, she has also successfully led antibody therapeutics from research phase into clinical trials. As Laboratory Head for the CRUK AstraZeneca Antibody Alliance, she collaborates with CRUK and the academic community to deliver a portfolio which spans different types of cancer with mAbs carrying antagonistic, Immuno-oncology, agonistic and ADC mechanisms of action. The Alliance team are working to get the best possible outcome for therapeutic and diagnostic programmes with the long-term goal of benefiting cancer patients.

• Display of Biologics

As ATUM’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company’s external communications. Prior to co-founding ATUM, Gustafsson was Scientist and later Manager at Maxygen Inc., where he led, managed and collaborated with key strategic teams for more than five years. He also held a Scientist position at Kosan Biosciences, as well as a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He holds 43 issued U.S. patents and has published >40 scientific papers. Gustafsson received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden (Heja Löven) where he studied translation under Prof Glenn Björk.

• Using Data Science to Maximise Protein Production

Ben Hackel is a Professor of Chemical Engineering and Materials Science at the University of Minnesota. He earned degrees in chemical engineering from the University of Wisconsin (B.S., advised by Eric Shusta) and MIT (PhD, advised by Dane Wittrup) and performed postdoctoral research in the radiology department at Stanford University (Sam Gambhir). Since its inception, the Hackel lab has applied protein engineering technologies to develop physiological molecular targeting agents for molecular diagnostics and targeted therapy, with a focus on oncology and infectious disease.

• Antibodies Against Membrane Protein Targets

Supriyadi Hafiz, M.Sc., Senior Scientist Formulation, Liquid Formulation R&D, Active & Formulation in the Process Solutions, Life science division of Merck KGaA, Darmstadt, Germany is with the company for 8 years, working in development of excipients for downstream processing and protein final formulations. Hafiz has a BS in Biotechnology from Esslingen University Applied Sciences and a MS in Biosystem Technology from Darmstadt University of Applied Sciences.

• Protein Stability & Formulation

Dr. Urs Hagemann has 12 years of experience in the field of Targeted Radiotherapy, contributing to the establishment of the Targeted Alpha Therapy platform at Bayer. He joined Bayer in Berlin in 2017, advancing TRT projects from research into clinical development. Urs Hagemann started his career in a biotech company (Affitech, Oslo/Norway 2008 - 2012) before joining Algeta (Oslo/Norway), which was subsequently acquired by Bayer. Since April 2022, he is an official group head within Oncology research at Bayer and as such is responsible for the TRT research pipeline. Dr. Urs Hagemann has a background in molecular biology and holds a PhD degree within protein engineering from the University of Freiburg/Germany.

• Engineering Antibodies & Beyond

Mojtaba is a senior machine learning (ML) scientist at Pfizer, conducting data-driven research in life sciences. Prior to Pfizer, he developed ML models and Python libraries at the University of California, Berkeley, and SUNY Buffalo with a focus on computational chemistry and protein engineering. His research interests include developing ML solutions to accelerate virtual screening of molecules, ab initio molecular dynamics simulation, and biotherapeutic discovery. Mojtaba received software fellowship from the Molecular Sciences Software Institute in 2018. His heart is always with open-source software solutions and FAIR data for molecular science research.

• Machine Learning Approaches for Protein Engineering: Part 2

After completing his degree in Pharmaceutical Biotechnology, Daniel joined Boehringer Ingelheim in the Quality Control Clinical Supply & Transfer Group. He quickly transitioned to his current role as a Process Expert in Cell Line Development (CLD). In the CLD group, Daniel is responsible for project coordination and is leading technology innovation projects focusing on advancing the generation and characterization of monoclonal manufacturing cell lines. Daniel's expertise extends to cell line development and genetic cell line characterization, including vector development, cell line engineering, and next-generation sequencing.

• Optimising Expression Platforms

Principal scientist in Global Research Technology, Novo Nordisk A/S. Focused on optimization of biophysical properties of industrial enzymes and proteins-specially formulation and developability optimization of biopharmaceuticals.

• Protein Stability & Formulation

Sophia Hober is Professor of Molecular Biotechnology at KTH, Stockholm, Sweden. The focus of her current research group is development of predictable and robust systems for protein purification and detection by protein design and various selection methodologies. Her key scientific achievements include design and development of gene fusion systems for selective ion-exchange purification and improvements of the alkaline tolerance of protein A for industrial purification of IgG (currently a product sold by GE-Health care). Also, a novel ligand for affinity purification of proteins has been developed that displays a calcium dependent binding, enabling mild elution from the column. Moreover, small bispecific protein domains with ability to strongly and selectively bind to two different proteins recently have been developed for use in diagnostic and therapeutic applications.

• Display of Biologics

Philipp Holliger is a Program Leader at the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK. Phil graduated from ETH Zürich and moved to the lab of Nobel Laureate Sir Greg Winter at the Cambridge Centre for Protein Engineering, for his PhD and postdoctoral studies in antibody engineering, before joining LMB as a program leader. Research in his group spans the fields of chemical biology, synthetic biology, and in vitro evolution and has been published in major journals (Nature, Science, Cell, etc.) as well as leading to numerous patents. His work, describing a range of novel synthetic genetic polymers (XNAs) has featured in Scientific American’s 10 World Changing Ideas. He is a member of EMBO and has been a consultant to several successful biotech companies including Cambridge Antibody Technology / Medimmune / Astra Zeneca, Solexa / Illumina, Domantis, and GSK.

• Display of Biologics

I have more than 20 years of experience in drug discovery. Currently I lead the Antibody Protein Science team within GSK's Large Molecule Discovery department. We have accountability for production and biophysical characterization of antibodies and other large molecules throughout the discovery process. Previous experience includes leading a multidisciplinary team to embed automation and in silico tools to accelerate GSK's Biopharm Drug Discovery process and also 6 years at Biotech company, Domantis.

• Protein Process Development

Tomoyuki Igawa, Ph.D., graduated and was awarded Ph.D. from the University of Tokyo. Dr. Igawa started his career at Chugai Pharmaceutical, a member of the Roche group, and has led the effort to develop novel antibody engineering technologies, such as bispecific antibody for Hemlibra® (emicizumab), recycling antibody for Enspring® (satralizumab) and crovalimab, half-life extension technology for Mitchga® (nemolizumab), and other various technologies applied to current Chugai/Roche pipeline products. After serving as CEO and Research Head of Chugai Singapore, and Head of Translational Research Division in Chugai Pharmaceutical, Dr. Igawa is currently responsible for drug discovery as a Head of Discovery Research Division. Dr. Igawa has published > 40 peer reviewed papers and is an inventor of > 100 patents in antibody drug discovery.

• Engineering Conjugates
• Machine Learning Approaches for Protein Engineering: Part 1
• Innovative CAR T Therapy
• Emerging Targets and Therapeutic Approaches
• Advancing Multispecifics and Combination Therapy to the Clinic
• Analytical Characterisation of Biotherapeutics
• Optimising Expression Platforms
• Engineering Antibodies & Beyond

Dr. Ippolito initially studied physics at Reed College before completing training in B-cell immunology at The University of Alabama at Birmingham, The University of Cologne (Germany), and The University of Texas at Austin. He is Research Associate Professor at UT Austin in Molecular Biosciences where he spearheads antibody technology development and the investigation of human immunology.

• Emerging Targets and Therapeutic Approaches

Melita Irving, originally from Canada, has been working in Lausanne, Switzerland in the field of T cell engineering since 2007. In 2013, she became a group leader for T cell engineering at the Ludwig Institute for Cancer Research of the University of Lausanne. Her research focuses on the development of function and safety enhanced TCR and CAR T cells and concomitant harnessing of innate and adaptive immunity to augment the control of solid tumors.

• Innovative CAR T Therapy

Rivka obtained a B.Sc. in Biochemistry from the University of Manchester in 1997, followed by a PhD in Chemistry from the University of Cambridge in 2001, under the supervision of Professor Sir Alan Fersht, FRS. She carried out post-doctoral research at Harvard Medical School with Professor Pamela Silver, and then at Imperial College London with Professor Steve Matthews. Subsequently, she worked at the Imperial College Drug Discovery Centre before starting her own research group in 2009 funded by an MRC New Investigator Research Grant. Rivka is passionate about radical interdisciplinarity, conducting many projects across the arts-sciences interface, including an ongoing multimedia collaboration with London Fine Art Studios called Viewing the Invisible, and a longstanding relationship with the Iris Murdoch Research Centre at Chichester University around science and literature. Rivka currently serves on the UKRI Physics of Life steering group and the executive committee for the national Collaborative Computing Project for NMR. She was the 2021 winner of the Judith Howard prize from the Biophysical Sciences Institute at Durham University and the 2024 winner of the British Biophysical Society Elspeth Garman Prize for Public Engagement.

• Using Data Science to Maximise Protein Production

Shinya Ishii is a member of Chugai's Discovery Biologics department. He joined Chugai in 2002, specializing in antibody identification using phage display libraries. In 2017, he joined Chugai Pharmabody Research in Singapore where he led antibody identification and antibody engineering. In 2020, he returned to Chugai, and his current work focuses on antibody identification and the development of CAR T related technology.

• Engineering the Next Generation of Bispecific Antibodies

Vishal (Vish) Kamat is an innovative and collaborative leader with 17 years of experience in the field of biotherapeutics and biophysical characterization of antibodies and proteins. He has supported the discovery and development of antibodies for 150+ targets which yielded 20 clinical drug candidates and 3 market-approved drugs - DUPIXENT, LIBTAYO, and EVKEEZA. He also has extensive experience in high throughput screening of antibodies using diverse platforms such as SPR, BLI, KinExA, Gyrolab, MSD and Luminex. His scientific excellence is evident by multiple peer-reviewed publications in high impact journals, patent approvals and IND reports. After a 12-year career at Regeneron Pharmaceuticals where he held positions of increasing responsibility from postdoctoral candidate to Sr. Staff Scientist, he worked as a Director of Antibody Characterization at Twist Biopharma and is currently working as a Senior Director of Protein Sciences at Ampersand Biomedicine. Vishal holds a PhD in Biomedical Engineering from Drexel University and BS in Electronics Engineering from University of Mumbai.

• SC2: Advanced Applications of SPR & BLI Biosensors for Drug Discovery and Development

Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team focused on the crosstalk between patient immunity and cancer and on the design of novel therapeutic agents. Key areas of research center on patient-derived B cells and their expressed antibodies, Fc-engineered antibodies of different isotypes, and antibody-drug conjugates for cancer therapy. Her group is the first to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. Sophia is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based anti-cancer agents.

• Modulating the Tumour Microenvironment

John Kenney is a Founder and President of Antibody Solutions, a contract research organization specializing in therapeutic antibody discovery and development. Dr. Kenney holds a Ph.D. in Pharmacology from the Université Louis Pasteur and has authored over 40 publications. Notable scientific accomplishments include the discovery of five novel therapeutic candidates currently in clinical trials. Business achievements include delivering antibodies to meet clients’ funding milestones, patent filings, and enabling therapeutic development agreements valued at over a billion dollars. His current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.

• Antibody-Based Cancer Therapies

Bruce received his Ph.D. in biochemistry and pharmacology from Tufts University School of Medicine and his B.S. in Chemistry from Washington University in St Louis. He is a co-inventor on more than 35 U.S. patents and patent applications, and he has a co-authored more than 55 scientific articles. Bruce brings to IGM more than thirty-five years of research, development and management experience in large and small biotechnology companies, including his extensive experience in many phases of early stage drug discovery and development. This experience spans target selection and discovery, in vitro biochemistry, in vivo efficacy models and all other aspects of the pre-clinical development of antibodies and proteins as therapeutic agents.

• Emerging Targets and Therapeutic Approaches

Philip M. Kim is a Professor at Donnelly Centre at the University of Toronto. He leads a research laboratory that integrates machine learning, physics-based modeling and wet/experimental methods for engineering of biologics. He is a Co-founder of Resolute Bio, a drug development startup company. He authored over 70 publications, 7 invention disclosures and 3 patent applications. Before to setting up his lab in 2009, he was a postdoctoral fellow at Yale University where he pioneered structural analyses of protein interactions networks and an associate with McKinsey & Co. He holds a Ph.D. from the Artificial Intelligence Laboratory and Department of Chemistry at the Massachusetts Institute of Technology and a B.S. in Biochemistry and Physics from the University of Tuebingen.

• SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions

Dr Astero Klampatsa (PhD) is a Team Leader in Cancer Immunotherapy at the Institute of Cancer Research, London, UK. She graduated with a BSc in Biological Sciences and an MSc by Research in Biomedicine from Lancaster University. She was awarded a PhD in Research Oncology in 2011 from Queen Mary’s College, University of London, UK. As a postdoctoral fellow, she gained expertise in CAR T cell immunotherapy and immunobiology of thoracic cancers at King’s College London, UK, and at the University of Pennsylvania, USA. Since 2019, Dr Klampatsa has been leading her own team, the Thoracic Oncology Immunotherapy Group, focusing on developing novel CAR T cell therapies for mesothelioma and lung cancer, as well as the immunobiology of these malignancies for identification of markers of response to immunotherapy.

• Innovative CAR T Therapy

Christian Klein, Distinguished Scientist, is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery 3 at the Roche Innovation Center Zurich (Roche Pharma Research & Early Development, pRED). Since 06/2019 he also acts as Site Head of RICZ. He specialized in the discovery, engineering, validation and preclinical development of therapeutic (bispecific) antibodies for cancer immunotherapy. During his 18-year tenure at Roche he has made major contributions to the preclinical development and approvals of GAZYVA(RO) (obinutuzumab, GA101), and to the preclinical development of 19 bispecific antibodies, immunocytokines and antibody fusion proteins entering clinical trials. He led research teams developing Roche’s novel bispecific antibody technologies, e.g., the CrossMAb technology and the immunocytokine and T cell bispecific antibody platforms. He obtained his diploma in biochemistry from University Tübingen and his doctorate in biochemistry from Technical University Munich. In 2017 he completed his habilitation in Biochemistry at the Ludwig-Maximilians University (LMU) in Munich, and since then is an external lecturer there.

• Engineering Conjugates
• Machine Learning Approaches for Protein Engineering: Part 1
• Innovative CAR T Therapy
• Emerging Targets and Therapeutic Approaches
• Advancing Multispecifics and Combination Therapy to the Clinic
• Engineering the Next Generation of Bispecific Antibodies
• Analytical Characterisation of Biotherapeutics
• Optimising Expression Platforms
• Engineering Antibodies & Beyond

Prof. Kobold is a board certified clinical pharmacologist and immunologist. He studied medicine in Germany, Switzerland and France. His postgraduate and residency training took him through Hamburg and Boston to Munich. In Munich, he established his research group focussing on cancer immunotherapy with a focus on T cells and antibodies. Since 2016, he serves as an attending physician in the division of clinical pharmacology at the University hospital of the LMU where he was appointed full Professor and deputy director of the division in 2019.

• Modulating the Tumour Microenvironment

Harald Kolmar is full professor at the Technische Universität Darmstadt, Germany where since 2005 he heads the Department of Applied Biochemistry. He holds a PhD and habilitation in biochemistry and molecular genetics from University of Tübingen and Göttingen. His current scientific interests mainly focus on protein engineering and design, nanobiotechnology, antibody engineering, chemical biology and development of tailor-made peptides and proteins for applications in diagnostics and therapy.

• Engineering the Next Generation of Bispecific Antibodies
• Display of Biologics

I was born in Athens in 1991 and studied chemistry at the Aristotle University of Thessaloniki in Greece. In 2016, I moved at the University of Bath in the UK where I completed my MSc studies and focused my attention on the synthesis of polyketides fragments, under the supervision of Professor S. D. Bull. Subsequently, I joined the industrial sector for 3 years and I have been employed by Manchester Organics Ltd (Runcorn, UK) and then by Syngenta (Stein, Switzerland), where I worked as an Organic and Research Chemist, respectively. In 2020, I joined Dr. G. Chaubet and Dr. A. Wagner group at the University of Strasbourg in France, under a Marie Sklodowska Curie scholarship, where I was involved in the development of novel bioconjugation methods for the selective modification of native and artificial proteins. During this time, I have attended two 4-month secondments-in UCL under the guidance of Professor V. Chudasama (London, UK) and in Spirochem (Basel, Switzerland)-where I dealt with the synthesis of novel pyridazinedione molecules and the preparation of new bicyclo[2.1.1]hexane compact modules, respectively. Currently, I am in the first year of my postdoc at the University of Strasbourg working on the development of novel immune oncology agents for tumour-selective modulation of the microenvironment.

• Engineering Conjugates

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research in Japan and later in Denmark. For the last 17 years Dan has been working with analytical development in the biopharmaceutical industry, on projects ranging from early discovery through to product registration. Clinical indications include bleeding disorders, neutropenia, autoimmune diseases and oncology. Dan currently works as a Principal Scientist at Symphogen, which is specialized in the development of antibodies and antibody mixtures for the treatment of cancer.

• Analytical Characterisation of Biotherapeutics

Dr. Krogsgaard is an Associate Professor with tenure in the Department of Pathology and the co-leader of the Tumor Immunology Program in the Perlmutter Cancer Center at New York University School of Medicine. She is the graduate advisor for the Inflammation and Immunology Program at NYU. Her laboratory combines cell biology, biochemistry and biophysics to explore mechanisms of T cell recognition, activation, migration and T-cell effector functions in mouse models of disease and in human tissues to developing new therapies for cancer, viral and autoimmune disease. She serves on NIH/NCI study sections and have been continuously funded by the NIH during her independent career. Dr. Krogsgaard was an Alfred Benzon Fellow, a Pew Scholar in the Biomedical Sciences, an American Cancer Society Research Scholar, a Cancer Research Institute Investigator, received the Mark Foundation ASPIRE Award and the Exceptional, Unconventional, Research Enabling Knowledge Advancement (EUREKA) Innovator Award from the NIH.

• Next-Generation Immunotherapies

Leo is an innovative leader responsible for the implementation and application of advanced spatial technologies within preclinical evaluations of biological therapeutics. This strategic role is instrumental in enhancing the efficacy of discovery workflows for cancer immunotherapy and other therapeutic modalities.

• Modulating the Tumour Microenvironment

Giulia Lambiase holds an MSc in Pharmacy from the University of Bologna and a PhD in Chemical and Biological Engineering from the University of Sheffield in partnership with AstraZeneca. Giulia is experienced in cutting-edge analytical methodologies for protein drug analysis with major focus on chromatography and mass spectrometry methods combined with automation. She is now a Senior Scientist in the Analytical Sciences team at AstraZeneca where she is in charge of CMC analytical development of new candidate drugs, the development and implementation of high-throughput analytical capabilities, and leads a working group focused on data science and AI applications in biopharmaceutical development.

• Protein Process Development

Dr. Juan José Lasarte is full professor of Immunology at the University of Navarra and the Director of the Immunology and Immunotherapy program at CIMA. His scientific activity has been focused on the mechanisms of induction of cellular and humoral immune responses and the development of antiviral and antitumor vaccines using peptides, recombinant proteins, viral vectors or adoptive T cell based therapies. He has participated in the publication of over 180 articles in international journals and has been co-inventor on 18 patents. Some of these patents are in clinical phases for the treatment of various pathologies.

• Innovative CAR T Therapy

Dr. Jesús Lavado García completed his PhD in bioprocess engineering, specializing in HIV-1 Gag VLPs, at Universitat Autònoma de Barcelona in 2021. Following his PhD, he relocated to Denmark in 2022 to pursue postdoctoral research on the cell density effect in mammalian cell cultures, supported by the prestigious Marie Curie Postdoctoral Fellowship. Currently, he is dedicated to exploring the impact of high cell density on cell culture physiology, particularly focusing on optimizing the production of viral particles. His research aims to enhance the scalability and efficiency of viral particle manufacturing processes in the biopharmaceutical industry.

• Optimising Expression Platforms

Aaron LeBeau, PhD is an Associate Professor in the Departments of Radiology and Pathology and Laboratory Medicine at the University of Wisconsin School of Medicine and Public Health. The LeBeau laboratory operates at the interface of synthetic biology and nuclear medicine with the goal of developing novel antibody-based molecular imaging probes and targeted therapeutics for cancer. Experts in antibody phage display, his laboratory has developed high-diversity human and mouse antibody libraries in addition to single-domain antibody libraries from naïve camelids and sharks. Dr. LeBeau was a double major at the University of Arizona receiving B.S. degrees in Molecular and Cellular Biology and Chemistry with a minor in Classical Art and Archaeology. He received his Ph.D. in Pharmacology from the Johns Hopkins University School of Medicine and was a Department of Defense Postdoctoral Fellow at the University of California San Francisco in the Department of Radiology. His laboratory relocated to the University of Wisconsin in June 2021 after seven years at the University of Minnesota. He has received many awards for his research, including from the Society of Nuclear Medicine and the Prostate Cancer Foundation

• Antibody-Based Cancer Therapies

Ji Min Lee is an Assoc Professor of Graduate School of Medical Science and Engineering at Korea Advanced Institute of Science and Technology (KAIST). Her research group uses interdisciplinary approaches in synthetic biology, engineering, and epigenetics to study innate biological systems and to develop new tools for basic science and biomedical applications. Dr. Lee’s translational interests span nucleotide or protein-based drug discovery and development for applications in oncology and regenerative medicine, and development of new technologies for overcoming current drug resistance. Dr. Lee obtained her PhD in Biological Sciences from the Seoul National University, where she also completed a postdoctoral fellowship in Epigenetics. Dr. Lee was previously Principal Scientist of Business Development team, Samsung Bioepis, and Research Staff of Therapeutic Antibody Group, Samsung Advanced Institute of Technology (SAIT).

• Modulating the Tumour Microenvironment

Dr. Lee founded ABL Bio in February 2016 with the vision to build a company that offers patients a better life based on innovative science. Recognizing that bispecific antibodies are the key to next-generation therapeutics, Dr. Lee has focused on diversifying ABL’s portfolio of bispecific antibody-based treatments for cancer and neurodegeneration. Under his leadership, ABL has advanced four bispecific antibodies into clinical trials, demonstrating unprecedented speed and commitment among South Korean biotechnology companies. Prior to ABL, Dr. Lee co-founded PharmAbcine where he oversaw all research and development for antibody therapeutic projects. Before that, he was responsible for drug discovery and preclinical development as the Head of the Bio Division at Hanwha Chemical. Dr. Lee also brings years of experience from global biopharmaceutical companies, including Chiron(Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies. Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School and UCSF. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.

• Antibody-Based Cancer Therapies

Jin is a pioneer of applying deep language models for understanding the structure and function of B-cell receptors from their amino acid sequence alone. Specifically, he is interested in how advances in natural language processing and self-supervised learning can enhance antibody discovery. At Alchemab, he is responsible for the company’s machine learning platform and is the technical lead for the partnership with NVIDIA. Previously, Jin was a senior bioinformatician at BenevolentAI, and was one of the main developers of the SAbDab and SAbPred tools from the University of Oxford.

• Machine Learning Approaches for Protein Engineering: Part 2

Eric Letouzé co-leads the "Integrated Cancer Genomics" (ICAGEN) team in Nantes cancer research institute (CRCI2NA). Throughout his career, he developed innovative computational strategies to analyze cancer genomics data and unravel the mechanisms of tumorigenesis. The ICAGEN team integrates cutting-edge single-cell multi-omics analysis of multiple myelomas in a clinical setting to understand the evolution of cancer cells fostering tumor progression and treatment resistance.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Dr. Jeanette Leusen received her PhD in 1995 at the University of Amsterdam (UvA), The Netherlands, studying neutrophils. Now she is PI on antibody therapy in the University Medical Center of an academic group of 22 FTE. She has co-authored 135 publications and is co-inventor on 10 patent applications. She is also scientific founder of a company called TigaTx developing engineered IgA for therapeutic application in oncology.

• Modulating the Tumour Microenvironment

Marta Lewandowska is a Program Lead at Mestag Therapeutics, bringing over 14 years of experience in the biopharmaceutical industry, working at antibody-based biotechs, including F-star developing antibody bispecifics, Crescendo focusing on antibody fragment technologies and Biosceptare utilising monoclonal antibodies in the field of immune-oncology. Marta has worked across the drug discovery process, from lead isolation to preclinical evaluation, with extensive experience in antibody engineering, protein sciences, display technologies and in vitro immune assays. Prior to Mestag, Marta held a position as a Team Leader at Iontas, where she was both a team and project leader responsible for implementing and executing antibody discovery campaigns for a range of drug discovery programs across oncology, immune-oncology and autoimmunity therapeutic areas.

• Emerging Targets and Therapeutic Approaches

Dr. Lin Li is a senior staff member in the Artificial Intelligence (AI) Technology Group at MIT Lincoln Laboratory. Her research is focused on advanced graph analytics, representation learning for relational and graph data, natural language processing, and AI for biosecurity and material science. She is currently investigating approaches on AI-driven experimental design for novel materials and biological systems and applications of AI for social good. Before joining Lincoln Laboratory in 2015, Li worked at the U.S. Army Research Laboratory in Adelphi, Maryland, as a postdoctoral researcher. Her research was on learning sparse representations of high-dimensional data and modeling dynamic patterns in collective behaviors of social agents. Li is a member of the Institute of Electrical and Electronics Engineers (IEEE). She received the 2014 Young Author Best Paper Award from the IEEE Signal Processing Society for her work on distributed principal subspace estimation in wireless sensor networks. Li received PhD and BS degrees in electrical and computer engineering from the University of California, Davis.

• Machine Learning Approaches for Protein Engineering: Part 2

I joined Genentech’s Department of Antibody Engineering in 2004. In my early years of research, I focused on the antibody discovery, engineering, and optimization using the approach of in vitro phage-displayed technique to support various disease areas in biology. In my recent 5 years, I engaged in the rabbit single B-cell culture and cloning technology for in vivo antibody discovery in many applications. In my 20 years of industrial experiences at Genentech, I am extremely gratified to have contributed numerous therapeutic antibodies to early development and beyond, including the first anti-TIGIT therapy (Tiragolumab) currently in clinical phase III for oncology indication to help cancer patients.

• Engineering Antibodies & Beyond

Since 2022, Giuseppe Licari has served as a Lead Scientist in Computational Structural Biology within the Global Drug Product Development department at Merck Serono SA. His work focuses on establishing computational platforms for the characterization and screening of biological molecules, as well as elucidating the role of excipients in protein stabilization. Previously, at Boehringer Ingelheim, he was instrumental in developing in silico approaches for developability assessments and predicting protein properties. After earning his PhD in Physical Chemistry from the University of Geneva in 2018, he pursued a postdoctoral position at the Theoretical and Computational Biophysics Group at the University of Illinois at Urbana-Champaign.

• Protein Stability & Formulation

Lars Linden is Head of Biologics Research at Bayer and responsible for all research activities covering antibodies, multi-specifics, therapeutic proteins and AAV biology. Lars joined Bayer in 2007 and has held various positions as lab head, group lead and director in in the Biologics Organization where he was responsible for production of antibody-based research compounds and tools for biologics projects of Bayer’s early research pipeline and also overseeing developability assessments for clinical candidates. Lars has also a track record of successfully leading preclinical research portfolio projects in oncology (ADCs and IO) and ophthalmology. Previously he had worked on structural biology of GPCRs and ion channels in a small biotech environment. Lars did his PhD in Structural Biology at the Max Planck Institute for Biochemistry/Technical University of Munich.

• Engineering Antibodies & Beyond

Anne Ljungars holds a PhD in immunotechnology from Lund University and 18+ years of experience in biotech industry and antibody drug development. She is currently working in the Preclinical team at BioInvent, Lund, Sweden, where she is responsible for antibody discovery and is a key person in the development of the phenotypic antibody-target discovery platform F.I.R.S.T.™ As a senior member of the team she has coordinated discovery efforts in several antibody drug projects, presently in preclinical or clinical development.

• Display of Biologics

Dr Logtenberg is a highly respected, successful serial life sciences entrepreneur. He is the founder, former CEO and President of Merus N.V (NASDAQ: MRUS), a clinical-stage oncology company, advancing treatments based on multi-specific antibodies. He was also the founder and CEO of U-BiSys, a Dutch biotechnology company that merged with Introgene to become Crucell N.V., serving as its Chief Scientific Officer. Crucell was acquired by Johnson & Johnson for $2.4 billion in 2011. Dr Logtenberg also founded the HUB foundation for organoid technology with Dr Hans Clevers, and served on both its Board of Directors and Supervisory Board. As an antibody expert, he is currently the chairman of the board of Forbion’s portfolio company Synox Therapeutics, a board member of Mestag Therapeutics, also in Forbion’s portfolio, and board member of the Forbion European Acquisition Corporation, the Special Purpose Acquisition Company (SPAC) raised by Forbion in December 2021. Dr Logtenberg received a PhD in immunology from Utrecht University and did his post-doctoral work at Columbia University, New York. He is currently Professor in Entrepreneurship in the Life Sciences at Utrecht University.

• Advancing Multispecifics and Combination Therapy to the Clinic

Rosa recently earned her PhD from the Danino lab at Columbia University in New York, NY. She is currently a Postdoctoral Research Fellow in the McAllister lab at MD Anderson in Houston, Texas. Her doctoral research generated a new strategy for solid tumor recognition by integrating the antigen-independent specificity of tumor-colonizing bacteria with the cytotoxicity of engineered T cells. Rosa is passionate about developing the interface between microbes and human immune cells to innovate new cell therapies for cancer treatment and beyond.

• Innovative CAR T Therapy

Elizabeth is a Scientific Leader in the Antibody-drug conjugate platform team within Large Molecule Discovery at GSK. In this role, she leads on the analytical characterisation of ADCs in discovery to support pipeline programs. Elizabeth has over 10 years’ experience in the field of ADCs and bioconjugation in both industry and academia. Previously she was a Team Leader at LifeArc, and holds a PhD from UCL, where she worked in the research groups of Prof James Baker and Prof Kerry Chester.

• Analytical Characterisation of Biotherapeutics

Simon Low is currently Senior Director of Biologics Discovery and Innovation at CUE Biopharma, leading the protein engineering and development of CUE Immuno-STAT platforms. Simon graduated from University of Kansas Medical Center as a protein chemist and has spent 20+ in the pharmaceutical and biotech industry, including Pfizer and BMS, working in the areas of structural biology, protein production, and characterization. His area of focus is in early discovery and novel technologies towards development of therapeutic molecules.

• Modulating the Tumour Microenvironment

Alex is the CEO of Diagonal Therapeutics. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts, and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation, and Technology from MIT Sloan School of Management, a PhD in Biophysics from Harvard University, an MSc in Molecular Biophysics, and a BSc in Mathematics and Physics from the Moscow Institute of Physics and Technology.

• Next-Generation Immunotherapies

Dr. Geir åge Løset has more than 20 years of academic and industrial experience within the biotechnology sector where his work has focused primarily on antibody, T cell receptor and MHC engineering by use of phage display. Dr. Løset earned his PhD at the University of Oslo and spent parts of his post-doctoral training at the CSIRO Molecular and Health Technologies in Melbourne, Australia. Dr. Løset is Chief Executive Officer and co-founder of Nextera AS. He is an associate member of the K.G. Jebsen Coeliac Disease Research Centre and an Associate Professor at the Department of Biosciences, University of Oslo.

• Display of Biologics

Ali Madani is the founder and CEO of Profluent, an AI startup in protein design, based in Berkeley, CA. Previously, he led machine learning research initiatives at Salesforce Research utilizing deep learning, language modeling, and computer vision. Most notably, Ali was the architect of the ProGen moonshot which advances generative modeling for protein design.

• Machine Learning Approaches for Protein Engineering: Part 2

Dr. Nicole Mai is a Principal Research Scientist in the Protein Science department at Immunocore, where she leads efforts to engineer soluble TCR therapies with high potency and specificity. She is also leading a cross-functional team through the intricate journey from biological exploration to the final stages of safety and manufacturability, culminating in the identification of promising candidate drug molecules. Dr. Mai holds a PhD from Newcastle University (UK) and a degree in Pharmaceutical Chemistry from the University of Parma (Italy).

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

PhD in Computational Biology from the University of Kansas, with a focus on data collection, analysis, and interpretation, as well as the development and implementation of cutting-edge in silico tools for drug discovery and design. Currently, as a Senior Scientist at Takeda Pharmaceuticals, I spearhead the design, characterization, and optimization of therapeutic candidate drugs through computational analysis of protein sequence and structure, computational protein design, and engineering. I'm deeply engaged in pioneering AI-driven approaches to generate human-like proteins, particularly in the domain of antibody-based therapeutics.

• SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions

Sara Mangsbo (PhD) is a Professor in antibody drugs at Uppsala University. Professor Mangsbo is a leader in the field of cancer immunotherapy and specifically in antibody-based drug delivery and synthetic long peptides and has been awarded the SITC team award within the SLP stream along with numerous awards for societal outreach activities. She is a serial entrepreneur and has founded Immuneed AB, a service provider of immunotoxicity measurements in human whole blood by the use of the ID.Flow system. She is the Chief Scientific Officer and co-founder of Strike Pharma AB. She drives a translational research project with the ambition and track record of taking research projects into clinical trial testing.

• Engineering Conjugates
• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Anna Mann is a postdoctoral researcher at the Institute of Immunology at the University Medical Center Hamburg-Eppendorf, Germany, in the lab of Friedrich Koch-Nolte. Her expertise lies in the retargeting of Adeno-associated virus (AAV) vectors by the use of single-domain antibodies or nanobodies. She has more than ten years of experience in engineering and use of nanobodies specific for membrane proteins like ecto-enzymes and ion channels.

• Antibodies Against Membrane Protein Targets

Paolo Marcatili is an associate professor at the Technical University of Denmark, where he leads the "AI for immunological molecules" group. He has developed many state-of-the-art tools for characterising the structure and function of molecules of immunological relevance, in particular antibodies and T cell receptors, by applying deep learning tools to integrate sequence and structural data.

• Machine Learning Approaches for Protein Engineering: Part 1

Graduated in Biology in 1998 and PhD in Biochemistry-Biophysics in 2003 from the Autonomous University of Barcelona (UAB). During the PhD I investigated the structural and functional effect of point mutations of the transmembrane protein bacteriorhodopsin. In 2003, as technical head of the Animal Tissue Bank of Catalonia (BTAC) at the UAB, in addition to being in charge of the animal tissue repository, I specialized in the diagnosis and research in veterinary neuropathology. In 2008, as a senior Priocat researcher at CReSA-IRTA, I carried out studies in neuropathology associated with animal prion diseases. In 2010 I also became the technical responsible for the Comparative Murine Pathology Unit (UPMiC) of the UAB from where we offered a complete histopathological diagnosis of laboratory animals. Finally, since 2016 I have been working at the Protein Production Platform (PPP), service of the Nanobiotechnology (NBT) group of the UAB, first as a senior technician and currently also as a coordinator of the service from where we offer a service specialized and personalized in the production and purification of recombinant proteins in different eukaryotic and prokaryotic expression systems. The PPP is part of Nanbiosis, a recognized singular scientific and technical infrastructure (ICTS) at the state level. Furthermore, as a member of the NBT group, I am part of the research group for the development of protein-based nanomedicines. I am also a member of CIBER’s Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).

• Protein Process Development

Dr. Antonio Marra is medical oncologist and physician scientist at the European Institute of Oncology (Milan, Italy). His research interest is focused on the application of genomics and artificial intelligence for biomarker discovery and development of novel therapies in solid tumors, with a specific focus on breast cancer.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Dr. Hironori Matsunaga is a Scientist at Daiichi Sankyo Co., Ltd. He obtained his PhD in Biological Science from The University of Tokyo. With 19 years of experience in pharmaceutical research, he has made significant contributions to the fields of molecular cell biology, biochemistry, pharmacology, small molecule screening, and ADC therapy research. His work has led to the discovery of clinical candidate compounds, including an mTOR inhibitor and an IDH1 mutant inhibitor. Currently, Dr. Matsunaga is focused on ADC therapy research, particularly on DXd ADC and other next-generation ADCs.

• Engineering Conjugates
• Machine Learning Approaches for Protein Engineering: Part 1
• Innovative CAR T Therapy
• Emerging Targets and Therapeutic Approaches
• Advancing Multispecifics and Combination Therapy to the Clinic
• Analytical Characterisation of Biotherapeutics
• Optimising Expression Platforms
• Engineering Antibodies & Beyond

Jenny Mattsson has 20+ years of experience in antibody discovery. She currently holds a position as Principal Scientist in the Preclinical Research department at BioInvent, Lund, Sweden. As a senior member of this team, she has coordinated discovery efforts in several antibody drug projects, currently in preclinical or clinical development, and she was a key person in building the phenotypic antibody-target discovery platform F.I.R.S.T.

• Antibodies Against Membrane Protein Targets

Madelon Maurice is appointed Full Professor at the UMC Utrecht and member of the national Oncode institute for cancer research. She is internationally recognized for contributing key mechanistic insights into how stem cell-niche communication controls tissue renewal, and how cancer mutations impact on these processes. Her academic group employs a multiscale approach that allows for the investigation of molecular processes in complex tissues using organoid-based model systems (https://madelonmauricelab.nl/). A longstanding interest is to understand ubiquitin-mediated regulation of key signaling pathways, highlighted by i) the discovery that the membrane-bound E3 ligase RNF43 controls Wnt receptor turnover in stem cells, and ii) the invention of SureTACs technology for targeted membrane protein degradation. The innovative nature of her work was recognized with various prestigious grants (e.g. ERC-St, NWO-VICI, ZonMW-TOP, national Gravitation grant IMAGINE!). Madelon coordinated the international Marie Sklowdoska Curie EU ITN consortium “WntsApp”, comprising 7 academic and 3 private sector European partners (2013-2017). Madelon is a regular invited speaker and organizer of international meetings (e.g. GRC, EMBO) and is co-chair of the Utrecht Platform for Organoid Technology. Fundamental research in the Maurice lab is integrated with ongoing efforts to translate findings into applications. In 2021, Madelon teamed up with seed investor ArgoBio and Oncode to found the biotech company Laigo Bio. At Laigo Bio, heterobispecific antibodies (SureTACs) are employed for proximity-induced degradation of membrane-bound proteins. Madelon is shareholder, Board member, and chair of the Scientific Advisory Board (SAB) of Laigo Bio.

• Antibodies Against Membrane Protein Targets

Dr. Yariv Mazor is a Senior Director at the department of Biologics Engineering in AstraZeneca. Yariv is leading the Antibody Technology group with 23 reports and co-leads multiple antibody bio-therapeutic programs into clinical development. Yariv received his Ph.D. in Biotechnology from Tel-Aviv University, Israel in 2005, where he studied and developed antibody therapeutics and antibody-drug conjugates for Cancer. He then pursued postdoctoral training at the Dept. of Chemical Engineering, University of Texas at Austin, TX under Prof. George Georgiou where he developed a novel platform for the selection and screening of engineered full-length IgG antibodies from libraries expressed in E. coli. Yariv is the co-inventor of >10 patents or patent applications and the author of >20 peer-reviewed papers.

• Engineering the Next Generation of Bispecific Antibodies

John McCafferty was one of the founders of Cambridge Antibody Technology (CAT, now Medimmune) in 1990 and published the first paper/patent describing antibody phage display. After 12 years at CAT he returned to academia at the Sanger Institute and the University of Cambridge. In 2012 John formed IONTAS, a small innovative biotechnology company using phage display to develop novel antibody therapeutics. IONTAS have also developed a novel technology for construction of very libraries in mammalian cells by using CRISPR/Cas 9 and TALE nucleases to efficiently direct the integration of a library of antibody genes into single genomic locus within a population of cells.

• Antibodies Against Membrane Protein Targets

Birthe received her PhD from Tübingen University for her research working on the biochemistry of tRNA-specific endonucleases at the Sloan Kettering Institute in New York. As a postdoc, she worked at the MRC Laboratory of Molecular Biology, Cambridge, before transitioning to biotech and working at Isogenica in Cambridge, United Kingdom. Since 2015 she works on genetic code expansion in mammalian cells at Karolinska Institute, Stockholm.

• Optimising Expression Platforms

Dr. Taha Merghoub is the Deputy Director of the Meyer Cancer Center at Weill Cornell Medicine (WCM), New York. He is also Professor of Pharmacology, Professor of Immunology Research in Medicine and Margaret and Herman Sokol Professor of Oncology Research at Weill Cornell Medicine (WCM), New York. He is the director of the Ludwig collaborative and swim across America laboratory at WCM. He received his BA degree from the University of Algiers, Algeria, and MS and PhD degrees with highest distinction from University of Paris, France. His thesis work focused on the study of genetic polymorphism in fetal hemoglobin gene in patients with sickle cell anemia and thalassemia. His findings provided insight to the correlation of genotypes and phenotypes in sickle cell anemia and thalassemia. After graduation, he pursued his postdoctoral research with Dr. Pier Paolo Pandolfi at Memorial Sloan Kettering Cancer Center (MSK). He characterized the transcriptional properties of the Pokemon (Zbtb7) gene and its role during development. He also played an active role in the generation of laboratory models for acute promyelocytic leukemia and furthered his knowledge and experience in genetics. He subsequently joined Alan Houghton laboratory as a Senior Research Scientist where he started studying tumor immunity. He developed mouse models of melanoma that mimic different stages of human disease clinically, pathologically and genetically, later evaluating new immunotherapies at different stages of tumor progression. He then became an assistant attending biologist in the melanoma and sarcoma service and assumed the direction of a research laboratory in partnership with Dr. Wolchok. He successively became associate attending in the melanoma and immunotherapeutic service to then become a full member in the Human Oncology and Pathogenesis Program (HOPP) department at MSK. He was also a Parker Institute member researcher and led the Melanoma disease management team (DMT) and the Immunotherapeutic group tissue bank at MSK. He was appointed in his current role at WCM in September 2022. He directs a translational tumor immunology laboratory at WCM. His current research projects focus on investigating the means for developing immune-based therapies to treat cancer. In addition, some of his work aims to study the pathogenesis and treatment of melanoma and is directed in part at developing tools to study melanoma and immune responses in multiple cancers. His projects are heavily collaborative in nature, within the institution and across different disciplines with multiple entities. His projects can be divided into the following categories: 1) overcoming resistance to immune checkpoint blockade therapy by modulating the immune system; 2) using the immune modulatory properties of modalities that target and kill tumor cells directly; 3) defining biomarkers and genetic determinants of response to immune therapy; and 4) developing a tissue repository for the immunotherapy and melanoma groups. Dr. Merghoub's findings have been published in prestigious journals including Science, Nature, Cell, Nature Medicine, Nature Immunology, Cancer Cell. He has an h-index of 75, over 35 830 citations which is considered at the top2% worldwide. Dr. Merghoub participated in multiple actions and initiatives to build bridges between the United States and Algeria. Over the years, he contributed to multiple organization including the Algerian American Foundation for Culture, Education, Science and Technology (AAF-CEST). He served on the board of the AAF-CEST from 2014 to 2021 and as AAF-CEST president from 2017 to 2020.

• Modulating the Tumour Microenvironment

After MD studies and internal medicine post graduate training at the Universities of Toulouse and Strasbourg, Prof. Denis Migliorini, completed his postgraduate training in medical oncology under the mentorship of Prof. Pierre-Yves Dietrich at the University Hospitals of Geneva (HUG) . From 2015 to 2016, he completed his clinical fellowship in neuro-oncology. He holds a DAS in clinical trial management from the University of Geneva (UNIGE) and became principal investigator of several early phase trials testing various anti-tumor immunotherapy approaches, including peptide vaccines for the treatment of glioblastoma. Starting 2017, he performed a 3 years post-doctoral fellowship at the Center for Cellular Immunotherapies, University of Pennsylvania, in the laboratories of Professor Carl June and Professor Avery D. Posey. He trained in synthetic biology and T cell engineering, disciplines that enabled the development of CAR-T cell technology. In 2019, he was awarded the Swiss Bridge Foundation Prize in recognition of his work identifying neurotoxicity mechanisms of engineered cell therapies. Returning to Switzerland in 2020, he was appointed assistant professor at the Department of Medicine of the Faculty of Medicine of the UNIGE, and holds the ISREC Foundation Chair in Brain Tumour Immunology. At the HUG, he is an attending physician, head of the Neuro-Oncology Unit and clinical coordinator of the Geneva brain tumor biobank. Professor Migliorini is a member of the CRTOH steering committee.

• Innovative CAR T Therapy

Enkelejda Miho is a professor of Digital Life Sciences and dean of the master's program in medical informatics at the University of Applied Sciences and Arts Northwestern Switzerland. She is head of the Laboratory of Artificial Intelligence in Health (aihealth.ch). The group’s research focuses on the emerging field of artificial intelligence applied to health. The group uses analytics for personalized medicine, drug discovery and development, and support systems in clinics. She is the founder of the ETH spin-off aiNET.

• Machine Learning Approaches for Protein Engineering: Part 2
• Machine Learning Approaches for Protein Engineering: Part 1

Goran completed his undergraduate studies in biochemistry at the University of Ljubljana, Slovenia. He then moved to Munich, Germany, to pursue his doctoral degree at the Max Planck Institute of Biochemistry, where he investigated the mechanisms of folding, assembly, and remodeling chaperones using a combination of biophysical methods and biochemistry. After completing his PhD, he conducted his postdoctoral training at Harvard Medical School, where he studied lung surfactant proteins. In May 2021, he joined Novartis Drug Product Development in Slovenia. His main responsibilities include modeling the 3D structures of various protein therapeutic formats, conducting sequence and structure analysis, performing MD simulations, implementing various machine learning models, protein engineering, and formulation development.

• Optimisation & Developability

During my academic formation, I have investigated the physiological relevance of several GPCRs and their interactors in brain function. When I joined the in vitro pharmacology team at UCB Biopharma in Belgium, I could participate in several drug discovery projects developing assays to track protein trafficking and protein-protein interaction affecting neuron vulnerability using from cell signalling profile to biophysical techniques. First as a scientist and afterwards leading NovAliX biology team, an insourced team of 8 scientists involved in early drug discovery. Beginning of 2021, I joined Galapagos Discovery Sciences Department, leading the setup of biochemical, biophysical, target engagement and target-based assays to support drug discovery pipeline.

• Analytical Characterisation of Biotherapeutics

Having completed her PhD (University of Kiel, Germany) characterising the mode of action and physicochemical properties of antibacterial proteins, Justyna undertook her post-doctoral studies at the Centre of Advanced Research in Biotechnology (Maryland) focused on the structural changes in G protein signaling. Justyna joined Almac in 2009 to work on the development of their proprietary technology focused on site-specific protein conjugation, before moving to Iksuda Therapeutics Ltd (previously Glythera Ltd) in 2013. Justyna is a Research Lead for Iksuda’s Research programs. She has over 10 years of industry experience in the development and pre-clinical exemplification of a variety of conjugation platforms in multiple ADC models. Justyna brings comprehensive knowledge of bioconjugation chemistry, pharmacology, and an understanding of ADC design and development.

• Engineering Conjugates

Shusuke Nambu is a biochemical scientist with ten years of experience working in Chugai. Shusuke specializes in structural characterization of bio-pharmaceutical product in CMC, especially using mass spectrometry, and also is responsible for CQA assessment. Before his joining Chugai, Shusuke worked as an assistant professor in a university and characterized structure of proteins and enzymatic activities using X-ray crystallography and several spectroscopy such as resonance Raman and electron paramagnetic resonance.

• Analytical Characterisation of Biotherapeutics

Kausheek is recognized as a global leader with over 15 years of experience in the Healthcare and IT sectors, where he has been instrumental in guiding teams, products, and programs in across Europe, Canada and US. His extensive leadership and technological expertise spans various domains within Healthcare, particularly in the realms of AI and Data Science. As the Director of Digital Transformation, his goal is to propel Boehringer Ingelheim and its Biotherapeutics division to the forefront of the Pharmaceutical R&D industry in terms of leveraging Artificial Intelligence and Machine Learning. He is dedicated to establishing the necessary infrastructure and foundation to foster innovation in these fields. Kausheek’s zeal lies in creating digital products through co-creation and external partnerships, enhancing patient health with AI and other technological advancements. His philosophy centers around the continuous cycle of learning, unlearning, and relearning, coupled with a proactive and collaborative mindset.

• Machine Learning Approaches for Protein Engineering: Part 1

Dr. Nastri is currently the VP of Protein Science and Technology at Incyte Corp. His group is responsible for end-to-end discovery and engineering of monoclonal and bispecific antibodies for oncology applications. His group uses both immunization, as well as display approaches for the generation of lead molecules, which are further optimized by a combination of in vitro and in silico approaches. Dr. Nastri started his career in the antibody field at Dyax Corp., where he developed and co-invented key technologies utilized to build the Dyax Fab libraries. He then headed the Antibody Technologies group at EMD Serono, where he implemented new approaches for selecting antibodies by single cell B-cloning and phage display. He became an Inventor of Avelumab, a clinical-approved anti PD-L1 antibody. He joined Pfizer CTI as a Biotherapeutic Site Head in NY, where he collaborated with local academic leaders to enable and advance novel therapeutic programs. During his career, Dr. Nastri became an inventor of multiple antibody therapeutic molecules and antibody discovery enable technologies, while participating in a number of projects resulting in IND applications.

• Engineering Conjugates

Dario Neri was born in Rome on 1 May 1963, but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became professor at ETH Zürich in 1996. Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders and on the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory conditions. Dario Neri has published 400 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.

• Next-Generation Immunotherapies

Graduated in Molecular Immunology in 1992 from the Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed phage display semi-synthetic human antibody library, the so call ‘Nissim’ library which has been used worldwide. In November 2000 was appointed at Queen Mary University. My studies are interdisciplinary and involve translational research at the William Harvey Research Institute and with intensive worldwide collaborations. My studies have been mostly focused on the mechanisms that lead to the formation of disease tissue-specific pathogenic post-translationally modified proteins and the exploitation of identified pathogenic proteins to develop platform technologies for novel disease - and tissue-specific, diagnosis and targeted treatment.

• Emerging Targets and Therapeutic Approaches
• Display of Biologics

Rajkumar Noubade is Director in Oncology department at Gilead Biosciences in Foster City, CA and has decades of experience in tumor immunology at various levels across industry. His lab focusses on investigating components of tumor microenvironment with the goal of potentiating anti-tumor immunity. He received his PhD from University of Vermont, Burlington VT and completed his postdoctoral training at Genentech, South San Francisco, CA. He has authored and co-authored several manuscripts in high impact journals.

• Modulating the Tumour Microenvironment

Professor Yanay Ofran is a computational biophysicist and a biotech entrepreneur. His scientific work uses computational approaches to understand, predict and engineer protein interactions. Yanay is the founder and CEO of Biolojic Design. Relying on big-data and machine learning, Biolojic’s platform mimics the way the human immune system makes antibodies to design functional antibodies that provide a precise molecular effect, in the desired micro-environment, at the right time, leading to greater efficacy and lower toxicity, while maintaining impeccable developability, half-life, stability and safety of human antibodies. He is also the co-founder of Ukko, a biotech company that uses computational tools and patient samples to design a novel and safe treatment for food allergies, and to design safe gluten for people with gluten sensitives. In 2020, Yanay co-founded Aulos Biosciences, which became the first company to treat cancer patients with a computationally designed antibody. Prof. Ofran headed the lab of systems biology and functional genomics at Bar Ilan University near Tel Aviv.

• Machine Learning Approaches for Protein Engineering: Part 1

Carlos Outeiral is an Eric and Wendy Schmidt AI in Science postdoctoral fellow at the University of Oxford, where he is also a Stipendiary Lecturer in Biochemistry. After earning BSc and MPhil degrees in chemistry in Oviedo and Manchester, Carlos completed a DPhil in Statistics at the University of Oxford, developing computational methods to study protein biosynthesis. Carlos' research focuses on developing artificial intelligence methods for in silico protein engineering, aiming to accelerate computational screening of therapeutics for stability and developability. Outside his work, Carlos is interested in Latin dancing, food science, and tech entrepreneurship.

• Machine Learning Approaches for Protein Engineering: Part 2

Marije Overdijk obtained her PhD in 2013 at Genmab (Utrecht, Netherlands), with a thesis on the role of Fc-gamma receptor mediated effector functions of therapeutic antibodies. She continued at Genmab as a Scientist working on the discovery and development of therapeutic antibodies, with a focus on oncology. Currently, she is team lead of the Translational Research Group at Genmab. Her team is responsible for the design and execution of the translational strategy for novel antibody compounds in preclinical and early clinical development, including the biomarker strategy for first-in-human trials.

• Advancing Multispecifics and Combination Therapy to the Clinic

Professor Paul W.H.I. Parren is dedicated to translating antibody knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Professor Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017, he led research and preclinical development at Genmab, and from 2018-2023 he was head of R&D at LAVA Therapeutics, a Nasdaq-traded biotechnology company that develops bispecific gamma-delta T cell engagers to transform cancer therapy. His work contributed to eight approved therapeutic antibodies (incorporated in ten antibody products), including multiple products from the DuoBody bispecific antibody platform. He has a strong publication record with >230 scientific publications (>37,000 citations and an h factor of 102; Google Scholar Jul. 7, 2023) and >220 granted patents in US, EU and JP). He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. He is CEO of Sparring Bioconsult BV, a consulting company that provides independent drug development advice. He is a founder and CSO at Gyes BV, a start-up company developing multi-specific antibody technologies. He chairs the board of directors of The Antibody Society, a non-profit trade organization that develops initiatives to forward the antibody field.

• Advancing Multispecifics and Combination Therapy to the Clinic

Ryan Peckner has been the head of machine learning at Seismic Therapeutic since early 2022, where he leads a team focused on applying ML to develop next-generation classes of non-immunogenic protein therapeutics. He earned his PhD in theoretical mathematics at Princeton University in 2015 and, after deciding to transition to an applied field, completed his postdoctoral training at the Broad Institute with an emphasis on the intersection of proteomics, genomics, and machine learning. Since entering biotech in early 2019, he has focused on developing and applying new machine learning techniques to structural biology, immunology, and drug development, beginning with models to probe TCR-pMHC interactions at Repertoire Immune Medicines and continuing with his work at Seismic.

• Machine Learning Approaches for Protein Engineering: Part 1

Mario Pereira has a diverse work experience history. Mario is currently the Director of Technology and Business Development at ATUM since March 2023. Prior to this, they worked at Horizon Discovery from 2016 to 2023 in various roles including Strategic Account Manager, Field Application Scientist, and Senior Scientist. At Horizon Discovery, they were responsible for commercial activities, technical input in pre and post-sales, and development of the CLD platform. Mario also worked as a Principal Scientist at FUJIFILM Diosynth Biotechnologies from 2015 to 2016, focusing on developing recombinant CHO cell lines. Mario Pereira completed their Biotechnology PhD at the University of Manchester from 2011 to 2015, where their research focused on genomic environment for recombinant gene expression. Mario has also been involved in various outreach and community activities, including roles at PARSUK and Oxbridge Biotech Roundtable. Mario Pereira began their education in 2005 at the Universidade de Coimbra, where they obtained a Bachelor of Science degree in Biochemistry in 2008. Following this, they pursued a Master of Science degree in Biochemistry from the same institution, completing their studies in 2010. Mario then continued their academic journey at The University of Manchester, where they enrolled in a Doctor of Philosophy program in Biotechnology. Mario successfully completed their PhD in 2015, thus furthering their expertise in the field.

• SC3: Tools for Cell Line Engineering and Development

PhD in Cellular Biology at the University of Tuebingen, Germany; Postdoctoral Fellow at MIT Cancer Center, Cambridge, USA; 6 years in Oncology R&D at Merck & Co., Boston, USA; since 9.5 years at Janssen Oncology R&D, Beerse, Belgium; current position: Senior Director Oncology, Global Head of Discovery Hematological Malignancies.

• Advancing Multispecifics and Combination Therapy to the Clinic

Andreas Plückthun, Ph.D., is a Professor of Biochemistry at the University of Zurich, Switzerland. His research on protein engineering has included pioneering work on antibody engineering, the development of ribosome display, new scaffolds (the DARPin technology and Armadillo Repeat Proteins), engineering of stable G-protein coupled receptors towards high stability, and most recently a new retargeting platform for gene therapy. He is member of the German Academy of Science (Leopoldina) and recipient of many international awards and founder of three biotech companies, Morphosys, Molecular Partners and G7(divested to Heptares/Sosei). Trained as chemist in Heidelberg, he received his Ph.D. at UC San Diego, was Postdoc at Harvard, group leader at the Max-Planck-Institute in Martinsried, and then Professor in Zurich. His work has been published in over 475 papers, which have been cited over 50,000 times. He is an inventor on more than 25 patent families.

• Machine Learning Approaches for Protein Engineering: Part 2

Dr. Simon Plyte has over 20 years of experience in research and development in the Pharma industry, both in Big Pharma and small Biotech. He has worked on the discovery and development of NCEs and Biologics, predominantly in the field of Oncology but has also worked in cardiovascular, neurodegeneration, and metabolic disease drug discovery. For the last 8 years, he has focused on Biologics drug discovery, using mono- and multi-specific formats predominantly in the field of Immune Oncology.

• Next-Generation Immunotherapies

No bio available.

• Machine Learning Approaches for Protein Engineering: Part 1

Nicolas Poirier has 15+ years of experience in immunotherapy target identification/validation, preclinical and translational drug development and partnership with pharmaceutical companies. He was awarded the Thesis Prize of the journal Le Monde. Nicolas Poirier has been chief scientific officer of OSE Immunotherapeutics since 2016. He joined the company in 2009 as project leader and then as director of scientific programs. Nicolas holds a Ph.D. in immunology and has a strong expertise in the development of immunotherapies. His role at OSE has been to implement innovative therapeutic strategies on new targets and pathways in immunology addressing severe pathologies with high therapeutic need in immuno-oncology and Inflammation, thus making a robust contribution to the Company’s growth. Along with his R&D team, Dr. Poirier continues pursuing the identification of novel preclinical targets and translating them into first-class clinical-stage immunotherapies. He is the author of 50+ high-level international publications and 30+ patents in the area of immunotherapy.

• Next-Generation Immunotherapies

She is a Drug Product Process Scientist and laboratory head for Biologics process in SANOFI since 2020. She covered all biologics drug product’s “Fill & Finish” manufacturing process development from lab-scale to pilot and commercial: freeze-thaw, bulk preparation, mixing, filtration, aseptic filling and freeze-drying, using process simulation and Quality by Design approach. She performed technical transfers from lab-scale to non-GMP & GMP pilot as well as industrial scale. She holds an engineer diploma specialized in process and chemical engineering.

• Protein Stability & Formulation

Héloïse hold a PhD in virology. She started her career in Sanofi Pasteur Val de Reuil, working as Influenza vaccine process and product specialist for three years. She then moved to DBV technologies, a biotech company developing immunotherapy for food allergy. In 2020, she joined Sanofi Ghent, where she is currently principal scientist in the CMC Pharmaceutical Development and Technology Analytics department.

• Protein Stability & Formulation

Dr. Laszlo Radvanyi is the President & Scientific Director of the Ontario Institute for Cancer Research (OICR; https://oicr.on.ca/) bringing over 30 years of oncology research background in academia and leadership experience in international pharma and biotech. He is also a Professor in the Immunology Department at the University of Toronto where his research focuses on the role of non-coding regions, including retrotransposable elements and human endogenous retroviruses, in cancer development and as modulators of the immune response in cancer patients. Laszlo joined OICR in 2018 from EMD Serono (Merck KGaA), where he was Senior Vice President Global Head of the Immuno-Oncology Translational Innovation Platform and Senior Scientific Advisor for Immunology and Immunotherapy (2015-2018). Prior to this, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for 10 years (2004-2014) where he ran an integrated clinical and basic cancer immunotherapy research program focusing on adoptive cell therapy. He left MD Anderson Cancer Center in 2014 to become the founding Chief Scientific Officer of Iovance Biotherapeutics (2014-2015), a pioneering company commercializing tumor-infiltrating lymphocyte (TIL) adoptive cell therapies for melanoma and other cancers which recently got its first TIL therapy product (lifileucel) approved by the US FDA in February 2024 under the product name AmtagviTM. Laszlo led the company in filing its first INDs and built its research and development team. Laszlo also sits on several national and international grant review panels and biotech advisory boards and is a sought-after expert in cancer biology and immunotherapy and a thought leader in the field of oncology research strategy.

• Modulating the Tumour Microenvironment

Jonah Rainey holds a PhD in Biochemistry from Tufts University and completed postdoctoral training at the University of Wisconsin and the Salk Institute. He has engaged in discovery, research, and development of bispecific antibodies for more than 15 years. He is an inventor on several patents describing novel bispecific platforms and current clinical candidates that exploit these platforms as well as an author on almost 30 publications. Jonah contributed to research and early development leading to multiple clinical candidates from Phase I and through approved products and led many advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Previous industry experience includes MacroGenics, MedImmune/AZ, Oriole Biotech, Gritstone Oncology, and Alivamab Discovery Services. Currently, Jonah is a Senior Director in Protein Science at Eli Lilly & Co.

• TS8A: Introduction to Multispecific Antibodies: History, Engineering, and Application

World’s leading expert Scientist in Antibody affinity and kinetic characterization, especially for measuring femto molar affinities of antibodies for soluble and on-cell targets. World expert in solution binding measurements and using KinExA technology. Extensive user of SPR and BLI technologies. Experienced SME as Functional Lead for human therapeutic antibody programs and drug product development. Dedicated career to advancing medical research to alleviate disease and make individuals lives better. Consultant for leading biotech organizations on high throughput screening, affinity measurements and antibody drug product development. Did extensive research, over 40 years in the fields of Endocrine Biochemistry, Molecular Endocrinology, Inflammation Immunology-Rheumatology, Human therapeutic antibody generation, engineering and characterization (including immunization, high throughput binding and functional screening and very high affinity kinetic measurements). A key member of a team of 5 Scientists who developed SLAM technology for human therapeutic antibody generation and spun to a Canadian Biotech company - Immgenics Inc., and later acquired by Amgen. First Scientist to generate human antibodies by Single Cell RT-PCR amplification of V genes from antibody producing single B Cells, molecular cloning and express as full antibody. Published over 40 articles in very high impact Scientific Journals and inventor of over 20 scientific patents. Worked for Amgen 25+ years and generated over 100 human therapeutic antibodies of which about 5 are already used as pharmaceutical drugs in market. Invited speaker in national and international conferences, Universities and Research institutes across the globe. Chaired sessions in international conferences and seminars. Dr. Palaniswami Rathanaswami graduated in MSc (Biochemistry, Faculty of Medicine) and a PhD (Biochemistry), University of Madras, India.

• TS9B: Label-Free Biosensor Tools in Biotherapeutic Discovery: SPR, BLI and KinExA

No bio available.

• Engineering the Next Generation of Bispecific Antibodies

Giuseppe Roscilli is a distinguished biotechnologist and Partner, serving as Chief Technology Officer (CTO) at Takis Biotech in Pomezia, Rome. Dr. Roscilli specializes in monoclonal antibody research and immune-oncology. He holds a PhD in Molecular Medicine from the University of Rome "La Sapienza," where he focused on drug resistance mechanisms and patient chemosensitivity. Dr. Roscilli has a rich background in antibody development. At IRBM (Merck&Co), he worked n voious fields from Monoclonal antibody development, to gene therapy and small molecule development where he was instrumental in identifying the PARP-1 inhibitor Niraparib, now used for treating ovarian cancer. At Takis Biotech, he initially directed the Drug Evaluation and Monoclonal Antibody Department, leading a team in generating and characterizing novel antibodies. Now, as CTO, he oversees strategic research projects and the integration of new technologies. His work emphasizes bispecific antibodies and T-cell engagers for cancer therapy. Dr. Roscilli has authored over 50 peer-reviewed papers and holds several patents in antibody and vaccine technologies.

• Next-Generation Immunotherapies

Professor Alan G. Ryder directs the Nanoscale Biophotonics Laboratory (NBL) which is based at the University of Galway (UoG) in Ireland. He has a BSc and PhD (1989) in chemistry from UoG. After a stint as a postdoctoral researcher in UCC, he rejoined UoG in 1997 to work on developing quantitative Raman spectroscopy-based methods for measuring illicit narcotics. In 2003, he formed the NBL which applies photonics and chemometrics technologies to applications in the life and physical sciences. In 2006, he obtained tenure in the School of Chemistry at UoG as senior lecturer and was promoted professor there in 2016. He has two core research areas: Analytical Sciences and Photonics, which cover a wide range of applications. In the Analytical Sciences domain, his main research area is developing of rapid, quantitative, analytical methods for the analysis of complex materials with particular focus on biopharmaceutical manufacturing and cell culture media analysis. He has collaborated with a wide range of biopharmaceutical manufacturing industries since 2004. He has authored more than 100 publications, generated 3 patents, and graduated 22 PhD students.

• Analytical Characterisation of Biotherapeutics

Kannan Sankar is a Senior Data Scientist in the Biologics Research Center at Novartis Biomedical Research. A structural bioinformatician by training, he works on combining sequence, structure, and dynamics with machine learning techniques to model the function and properties of biotherapeutics, as well as their interaction with targets. He holds a PhD in Bioinformatics and Computational Biology from Iowa State University, where he worked on developing knowledge-based in silico methods to understand sequence-structure-dynamics relationship in proteins. Prior to joining Novartis, he was a postdoctoral fellow at Genentech and Schrodinger, where he developed computational methods to predict the developability of antibody-based therapeutics.

• Protein Stability & Formulation

Giovanna Scaramuzzino has a master’s degree in computer science, and she is a software developer for HSG Engineering company. She is passionate about technology and deep learning, which is why she participated in the development of the intelligent fermenter project financed by the Italian Ministry of Economic Development. In her spare time, she enjoys play board games, traveling and having aperitifs with friends.

• Using Data Science to Maximise Protein Production

Volker Schellenberger is President and CTO of Amunix Pharmaceuticals, which he co-founded in 2006. He initially served as Amunix’s Chief Scientific Officer and is the lead inventor of the company’s XTEN as well as XPAT platforms of protease-activated T cell engagers. Volker has over 25 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department. Volker received his PhD from Leipzig University (Germany) in 1986. He is author of over 40 scientific papers and inventor of more than 70 issued or pending patent applications. He is a recipient of the Karl Lohmann prize of the German Society of Biochemists. Amunix was acquired by Sanofi in 2022. Since then, Volker has been Head of Discovery for precision-activated biologics.

• Antibody-Based Cancer Therapies

Peter conducted his PhD at Bayer Healthcare in Wuppertal, Germany, in the area of nitric oxide-independent blood pressure regulation. Based on this work, he got awarded an Alexander-von-Humboldt Fellowship to continue his research at the department of Pharmacology at Monash University in Melbourne. He left academia to join CSIRO and, after 4 years, took over the position as Senior Scientist in CSL’s R&D department in Melbourne, Australia. After 13 years in Australia Peter relocated to Germany to run the department of Recombinant Technologies covering all aspects of the early development of new biologics. After his assignment, Peter returned to Australia and is now heading the Protein Biochemistry group at CSL's research site in Melbourne.

• Protein Process Development

Simone joined Memo Therapeutics AG in 2014 and was instrumental in building MTx’s high-throughput microfluidic antibody platform. Prior to working at MTx, she gained experience in building new technologies during her Scientist position at Delenex Therapeutics, a scFv platform company. Simone obtained her PhD in Protein Biochemistry in the lab of Prof. Dr. Dr. Neupert at the LMU Munich.

• Emerging Targets and Therapeutic Approaches

Anna obtained her BSc in Medical Microbiology and Immunology from the University of Newcastle upon Tyne, UK and was awarded a PhD in Biomedicine from the University of Bonn, Germany, in Professor Percy Knolle’s lab, where she studied antigen cross-presentation and tolerance induction in the liver. She then moved to the lab of Professor Mala Maini at UCL, UK, working on the regulation of T cell exhaustion in chronic viral hepatitis B patients. In 2017 she was appointed as lecturer in the Department of Infectious Diseases at King's. Her research focuses on the metabolic regulation of human T cell responses in the context of chronic antigen stimulation, such as found in viral infections and cancer. Anna is a founding member and treasurer of the British Society for Immunology (BSI) Immunometabolism Affinity Group

• Innovative CAR T Therapy

Dr. Schuurman’s career centers around the antibody molecule as a biological source of inspiration and therapeutic modality. Dr. Schuurman joined Genmab’s R&D team in 2000 as one of the first scientists-her most recent position being Senior Vice President heading Genmab’s Antibody Research and Technologies. She is a co-inventor of many therapeutic antibodies and of the DuoBody, HexaBody, and HexElect technologies, which enable the generation of bispecific and effector-function enhanced antibodies. These technologies are being applied to antibody therapeutic discovery programs at leading pharmaceutical and biotechnology companies worldwide and have resulted in FDA-approved therapies such as RYBREVANT (amivantamab), EPKINLY (epcoritamab), TECVAYLY (teclistamab), and TALVEY (talquatamab). Dr. Schuurman has championed many successful academic and industry partnerships in antibody therapeutics and complementary research fields. Dr. Schuurman joined The Antibody Society’s Board of Directors in 2020 and currently serves as President of this international, non-profit trade association which represents individuals and organizations involved in antibody-related research and development. Dr. Schuurman is frequently invited to serve as a speaker, as well as a chair, at scientific conferences around the world due to her vision, impactful scientific publication track record, and dynamic presentations. She received her PhD in immunology from the University of Amsterdam. Dr. Schuurman is currently an independent biotech consultant (Lust for Life Science B.V.) and collaborates with many organizations, including Bioqube Ventures and Cartography Biosciences.

• Advancing Multispecifics and Combination Therapy to the Clinic
• Modulating the Tumour Microenvironment

Isabelle Sermadiras is a Biotechnology Engineer trained in Bordeaux, France. Her journey began in Belfast, where she worked as a Purification Scientist at Fusion Antibodies. In 2010, she joined AstraZeneca (formerly MedImmune) as a Protein Engineer and Scientist, contributing significantly to various drug projects involving peptides, monoclonal antibodies, and multispecifics. Recently, Isabelle transitioned from the lab to pursue her passion for data science and computational structural biology.

• Optimisation & Developability

Andrew Sewell initially trained in Chemistry and undertook a PhD in Genetics at the University of Liverpool (1991) before embarking on postdoctoral training at the University of Utah. He returned to the UK in 1995 to research how the HIV virus evades the human immune system at the Nuffield Department of Medicine, University of Oxford where he became a Wellcome Trust Senior Fellow. He relocated to Cardiff University in 2006 and became a Wellcome Trust Senior Investigator and has been continuously Wellcome-funded for over 25 years. His research group focuses on T-cell ligands and the receptors that recognise them (αβTCR, γδTCR, CD4 and CD8). Most of the Sewell laboratory’s recent work is based around understanding the basic biology of antigen recognition by human T-cells using novel pipelines for the discovery of new T-cell targets. Current Sewell group research projects include: Dissection of successful immune responses after successful cancer immunotherapy; TCR gene transfer therapy (TCR-T); Novel CAR-T technologies; T-cell receptor-optimised peptide skewing or the repertoire of T-cells (TOPSORT); Artificial (non-biologic) T-cell antigens as vaccines; T-cell/TCR-based diagnostics in autoimmune disease; and unconventional (non-HLA-restricted) T-cell responses to infection and tumours.

• Next-Generation Immunotherapies

Dr. Shan boasts an impressive tenure exceeding eleven years in early-stage of ADC research, following his postdoctoral and doctoral studies. As the Head of ADC Chemistry, he leads a dynamic team of scientists and technicians who play a pivotal role in spearheading ADC discovery initiatives. The synergy among diverse disciplines, including Biology, Chemistry, Toxicology, and CMC, has culminated in noteworthy milestones. alongside his pivotal contributation on TOPO1i ADCs, his insights also enhance the discovery of groundbreaking linker-payload technologies tailored for Oncology, Immuno-Oncology, and Immunology.

• Engineering Conjugates

Amir Shanehsazzadeh, Staff AI Scientist, develops generative models for antibodies and works at the interface of AI and wet lab, designing large libraries of antibodies for high-throughput screening. He leads the AI research team at Absci. Prior to joining Absci, he worked on ML-guided AAV capsid design for gene therapy at Dyno Therapeutics and researched ML for proteins at Google Brain, D. E. Shaw Research, and Fox Chase Cancer Center. He graduated from Harvard University, receiving a BA in Mathematics and MS in Statistics.

• Machine Learning Approaches for Protein Engineering: Part 1

Yang Shen, PhD, joined Regeneron in 2018 and currently serves as Executive Director, Antibody Engineering in Bispecific Department and Co-Chair of Protein Therapeutics, Pipeline & Technology Section. Yang founded Antibody Engineering Group and played an instrumental role in establishing Altibody platform. He and his team work on designing, producing, and screening alternative format molecules to deepen our understanding of biology and create new therapeutic opportunities at Regeneron. He received his PhD in Structural Biology from Columbia University. Prior to joining Regeneron, Yang held increasing roles at ImClone Systems and Eli Lilly between 2008 and 2018.

• Engineering the Next Generation of Bispecific Antibodies

Arun K. Shukla is currently the Joy Gill Chair Professor and senior Fellow of the DBT/Wellcome Trust India Alliance in the Department of Biological Sciences and Bioengineering at the Indian Institute of Technology, Kanpur, India. Before joining IIT Kanpur, he carried out his doctoral research at the Max Planck Institute of Biophysics in Frankfurt, Germany, and his post-doctoral research at the Duke University in Durham, North Carolina, USA. The research program in Dr. Shukla’s laboratory is focused on understanding the structure and function of G Protein-Coupled Receptors (GPCRs), the largest family of cell surface receptors in the human genome and one of the most important classes of therapeutic targets.

• Antibodies Against Membrane Protein Targets

Renu Singh holds a Ph.D in Pharmaceutical Science from the University of Montreal, Canada. Renu also holds a Clinical Pharmacokinetics certification from the University of Georgia. Renu's professional journey is marked by her tenure at distinguished organizations, including GSK, Bristol Meyers Squibb (USA), National Research Council of Canada, AstraZeneca R&D, Montreal (Canada), Charles River Laboratories Preclinical Services, Montreal (Canada), and Daiichi Sankyo Life Sciences Research Centre. She also held the position of Founding Director at Estella Biopharma. Her extensive expertise encompasses various facets of DMPK and early Clinical Development, including ADME, pre‐clinical and early clinical development, PK/PD modelling of small molecules and biologics, DDI prediction, human dose predictions, and ADME studies in clinical development for drug labelling.

• Antibody-Based Cancer Therapies

Dr. Corey Smith is a Principal Research Scientist in Cell and Protein Sciences/Biotherapeutics at the AbbVie Bioresearch Center (ABC) in Worcester, MA. He is responsible for protein purification and has specialized in the design, expression, and purification of Virus-Like Particles, enzymes, and protein complexes to advance the Biologics pipeline. Prior to joining AbbVie, he completed his post-doctoral work at UMASS Medical School in Dr. Paul Kaufman’s lab, working on involvement of histone chaperones in replication-coupled chromatin assembly and chromatin association with the nucleolus. His graduate thesis was completed under the guidance of Dr. Craig Peterson, UMASS Medical, where he worked on structural and enzymatic analysis of SWI/SNF chromatin remodeling complexes.

• Antibodies Against Membrane Protein Targets

Caroline Soulas, PhD, is a senior project manager at Innate Pharma, Marseille, France, a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. After completing her PhD in Immunology at the University of Geneva, Switzerland, she worked as a postdoctoral researcher in Neuroimmunology at Beth Israel Deaconess Medical Center and Boston College in Boston, MA, USA to study the role of immune cells in neuroAIDS. She has worked at Innate Pharma for over 12 years, first as a scientist, then holding positions as project manager and team leader within the pharmacology department. She is currently a CMC project manager in the pharmaceutical operations department.

• Engineering Conjugates

Ângela Sousa completed her PhD in Biochemistry (2011), was awarded two postdoctoral grants (2012, 2015), and is Assistant Researcher at Health Sciences Research Centre, University of Beira Interior (CICS-UBI), Portugal (since 2018) and Invited Assistant Professor at UBI (since 2017). Her research interests include biotechnological processes for the biosynthesis, isolation and purification of biopharmaceuticals (plasmids, and the innovative minicircle DNA) for DNA vaccines and gene therapy approaches against cervical cancer, lung cancer and COVID-19. She is also devoted to biotechnological processes to recombinantly produce HPV E6 and E7 oncoproteins and find potential natural or synthetic drugs (inhibitors) anti-HPV, by in silico (molecular docking), biophysical and in vitro studies.

• Protein Process Development

Laura Spector is a Scientist at Specifica, a Q2 Solutions Company in Santa Fe, NM, where she develops bioinformatics solutions to accelerate antibody discovery, including cloud-based software tools for antibody annotation and candidate lead selection. Her work has resulted in several high-impact publications as well as R&D solutions to improve next-generation sequencing of antibody libraries for database development. Prior to joining Specifica, she earned her PhD in Genetics at Stanford University, where she studied genomic factors influencing a virus-mediated gene therapy platform.

• Machine Learning Approaches for Protein Engineering: Part 2

Roberto Spreafico is the Senior Director of Discovery Data Science at Genmab. After earning an MSc in Biotechnology and a PhD in Immunology from the University of Milano-Bicocca in Italy, Roberto spent 10 years in the USA. There, he worked for institutions such as the University of California Los Angeles, Synthetic Genomics, and Vir Biotechnology, where he was the lead computational biologist on the team that developed Sotrovimab during the COVID-19 pandemic. Since returning to Europe, he has held managerial roles at GlaxoSmithKline and Absci before joining Genmab in September 2022. His expertise encompasses immunology, genomics, bioinformatics, and artificial intelligence.

• Machine Learning Approaches for Protein Engineering: Part 1

No bio available.

• Antibody-Based Cancer Therapies

Philipp Spycher is the CSO at Araris Biotech AG. As the inventor of the Araris ADC Technology, he has a profound background in Bioconjugation and ADCs. He was the founder CEO, positioning Araris to shift the paradigm in how to think about developing targeted cancer therapies. During his post-doctoral work at the Paul Scherrer Institute (PSI, Switzerland), he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris ADC Technology. Philipp won the PSI Founder Fellowship as well as several other prices and grants to commercialize the technology. He obtained his Master’s Degree and Ph.D. from ETH Zurich (Switzerland) at the interface of Material Science and Protein Engineering.

• Engineering Conjugates

Heading antibody discovery and engineering at Ossianix since 2015. We are utilising single domain antibodies to tackle the problem of brain delivery of therapeutic payloads across the blood-brain-barrier. Prior to joining Ossianix, I was working at Medimmune on intracellular delivery of biologics and as Research Director at Psynova Neurotech.

• Engineering Antibodies & Beyond

I am a Senior Lecturer in Biochemistry at the University of Liverpool's School of Biosciences, where I also serve as the programme director for the biochemistry degree. Previously, I held positions including Associate Professor of Biochemistry at Eastern New Mexico University (2010-2017), Assistant Professor at Mount Allison University (2008-2010), and completed post-doctoral research at the University of Toronto (2004-2008) after obtaining my PhD from Cambridge University (1999-2004). I have diverse experience including roles as an English and Chemistry Teacher in Jalisco, Mexico (1998-1999), a Research Scientist at GlaxoSmithKline (1996-1997), and as an undergraduate at Leeds University (1994-1998). My research focuses on utilizing biophysical tools to investigate protein structure, dynamics, and interactions, with a particular emphasis on understanding protein interaction specificity. Additionally, I am passionate about pedagogical research aimed at enhancing student success in laboratory settings.

• Protein Process Development

After graduating in Medicine at Campus Bio-Medico University of Rome in 2008, I have carried out a PhD at Queen Mary University of London under the supervision of Prof. Ahuva Nissim (from 2010 to 2014) and then a medical specialization in Endocrinology and Metabolic Diseases under the supervision of Prof. Paolo Pozzilli (from 2012 to 2016). Currently, I am Associate Professor of Endocrinology at San Raffaele University of Rome. My primary research activity aims to investigate the role of oxidative post-translational modifications of insulin and other beta cell antigens in the pathogenesis of type 1 diabetes. The final objective is to develop novel diagnostic biomarkers and target therapies for cure or prevention of type 1 diabetes, based on oxidative modifications of insulin. Main achievements of my research include the identification of antibody and T cell responses towards neo-antigenic insulin peptides induced by oxidative modifications. I have received several national and international awards, and since 2013, my research has been supported by competitive grants founded by the European Foundation for the Study of Diabetes, the Juvenile Diabetes Research Foundation, the Italian Ministry of Health and the Italian Ministry of University. Additional research activities are focused on: i) the effect of obesity and diabetes on bone metabolism; ii) the effect of glucose on immune response to SARS-CoV-2 as well as biomarkers of COVID-19 severity in patients with diabetes or obesity

• Emerging Targets and Therapeutic Approaches

Dr. Svilenov is currently an Associate Professor at the Faculty of Pharmaceutical Sciences, Ghent University. His research interests are in the development, formulation and manufacturing aspects of biotherapeutics. Before joining UGent, Dr. Svilenov was a postdoctoral researcher funded by a Peter and Traudl Engelhorn Fellowship and a grant from the Else Kröner-Fresenius Foundation in the group of Prof. Johannes Buchner at the Technical University of Munich. From 2016 to 2019, Dr. Svilenov did his PhD training supported by a Marie Sklodowska-Curie Fellowship under the supervision of Prof. Gerhard Winter at the Ludwig Maximilian University of Munich. He defended his doctoral thesis with the highest distinctions in Germany (summa cum laude) and received the AbbVie prize and the Carl-Wilhelm-Scheele of the German Pharmaceutical Society for his work. Dr. Svilenov is a pharmacist by training.

• Analytical Characterisation of Biotherapeutics

Li Tang received his B.S. in Chemistry from Peking University, China, in 2007, and Ph.D. in Materials Science and Engineering from University of Illinois at Urbana-Champaign, USA, in 2012, under the supervision of Prof. Jianjun Cheng. He was an CRI Irvington Postdoctoral Fellow in the laboratory of Prof. Darrell Irvine at Massachusetts Institute of Technology during 2013-2016. He joined the faculty of Institute of Bioengineering, and Institute of Materials Science & Engineering, at école polytechnique fédérale de Lausanne (EPFL), Switzerland, as a Tenure-Track Assistant Professor in 2016, and promoted to Associate Professor with tenure in 2022. His research focuses on developing multidimensional immunoengineering approaches for enhanced cancer immunotherapies. Dr. Tang is the recipient of Cancer Research Institute CLIP Award (2021), Anna Fuller Award (2021 and 2022), and named in the MIT Technology Review’s "Top 35 Innovators under Age 35" list of China region (2020), Materials Horizons Emerging Investigator (2020), Biomaterials Science Emerging Investigator (2019), and the recipient of European Research Council (ERC) starting grant (2018), and Nano Research Young Innovator Award (NR 45 under 45) (2018).

• Innovative CAR T Therapy

I am a postdoc at EBI, working on a project in collaboration with AstraZeneca and SGC. My research interests are in using AI for modelling chemical and biological systems. Prior to doing a masters and a PhD in bioinformatics at Imperial College London, I had worked for many years in financial sector IT. When not working and not looking after my young son, I like to spend my free time outdoors.

• Using Data Science to Maximise Protein Production

Dr Themeli studied Medicine in the University of Patras, Greece. After graduating, she did her PhD at the Bone Marrow Transplantation laboratory at the University of Patras Medical School studying the long-term biological consequences of GvHD in epithelial tissues after allogeneic hematopoietic cell transplantation. After completing her PhD training, Dr. Themeli joined the lab of Dr. Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. There she trained in the design and development of chimeric antigen receptor-engineered T cells (CAR T) and reported for the first time the use of induced pluripotent stem cells (iPSC) as an off-the-shelf source of therapeutic CAR T cells. In 2015. joined the department of Hematology at Amsterdam UMC-location VUmc, where, in 2017, she became Assistant Professor. Her research efforts focus on two different but related goals, connected by the global aim of developing next-generation cancer immunotherapy with CAR T cells: the broadening of its applicability and the improvement of efficacy and safety. Dr. Themeli has received several prestigious fellowships and awards such as: NYSCF Druckenmiller fellowship, ASH/EHA TRTH Career development award, Marie Curie individual fellowship and Innovation award from Argo-the Brussels Hellenic Network.

• Innovative CAR T Therapy

Gareth Thomas is Professor of Experimental Pathology at the University of Southampton and a clinical pathologist at University Hospital Southampton. His laboratory works on the tumour microenvironment, investigating the role of cancer-associated fibroblasts (CAF) in promoting tumour progression and treatment resistance. His lab uses a variety of technologies including 3D organoids, murine models, and ex vivo single cell transcriptomics to characterise CAF phenotype and function, investigating functional interactions with immune cells and identifying targetable pathways to overcome CAF-mediated immunotherapy resistance.

• Modulating the Tumour Microenvironment

Sophie received her PhD in T cell vaccine immunology from the Université Paris Cité, France. Following her postdoctoral trainings at Imperial College London, she worked at the Pasteur Institute on HIV vaccine design, then progressed to Stallergenes-Greer and ITS. There, she led the pre-clinical immunology teams, assessing respiratory allergic diseases desensitization immunotherapy and vaccines for infectious diseases, respectively. She transitioned to the French National Research Institute for Health and Medical Research in 2012 as a key leadership member of the IMI-funded ABIRISK project, a consortium focused on the analysis of underlying biological mechanisms, clinical relevance, and prediction of unwanted immunogenicity of biopharmaceuticals. Sophie joined Pfizer’s BioMedicine department in 2017 where she now leads the Immunogenicity Sciences group, in charge of immunogenicity risk assessment of Pfizer biologics portfolio at all stages of development. She also acts as Director of Scientific Affairs for the European Immunogenicity Platform.

• SC6: Introduction to Immunogenicity of Biotherapeutics

Mark Trautwein is an accomplished Leader in Biologics Drug Discovery and Development with more than 15 years’ experience. Mark obtained his doctorate in biochemistry from University of Tübingen, Germany. In 2008, Mark joined Bayer to establish mammalian protein expression platforms spanning the production of protein therapeutics, antigens, antibodies, and multispecifics, as well as cell line development. Mark has a track record of successfully advancing projects with different degrees of maturity within oncology as well as ophthalmology, comprising mAbs, antibody-drug conjugates, radioimmunoconjugates and various other formats. Mark has since then also grown an expert in Antibody Discovery, Optimization & Engineering. He is currently Head of Immunoprofiling Group, focusing on antibody effector function, immunogenicity research and experimental immunology.

• Optimisation & Developability

During my career, I have continuously focused on complement and (auto)antibodies. In my PhD-studies I became fascinated by the pathological consequences of complement and autoantibodies and was the first to show the pathogenicity of anti-C1q autoantibodies (J.Clin.Invest.2004). My post-doc studies in Sweden, revealed the importance of complement-inhibitors binding to free-DNA and dead cells (J.Exp.Med.2005). Subsequently, I choose to work (supported by a Veni-grant) in the Dept. of Rheumatology, LUMC, to implement obtained knowledge on complement and autoantibodies in a clinical setting. Several autoantibodies are known in Rheumatoid Arthritis but in 2011, with my team, I discovered a new autoantibody recognizing carbamylated-proteins (Proc.Natl.Acad.Sci.2011). During the last five years, using my Vidi-grant, I have unravelled the anti-CarP antibody response in depth and observed that they are present years before disease onset and are associated with development of RA and with disease severity. The predictive, diagnostic and prognostic properties have now been replicated in several international studies and following patenting, a commercial test is now being developed. How autoantibodies contribute to arthritis is still unknown, but I have demonstrated the complement activating potential of RA-associated antibodies. With my ERC-grant, we study the role of complement in autoantibody responses develop against modified self-proteins. In addition, I planned to use my expertise in complement and autoantibodies to develop modified-autoantibodies as therapeutics. Therefore, I have moved my group from the Rheumatology to the Immuno-Haematology (LUMC), one of the top Dutch immunology departments focusing on multiple disease areas, allowing a broad implementation of our findings.

• Advancing Multispecifics and Combination Therapy to the Clinic

Dr. Isabelle Turbica serves as Assistant Professor in Biotechnology at the School of Pharmacy of Paris-Saclay University since 2002, with skills that focus on therapeutic protein engineering and production. In particular, she is in charge of the Master's degree “Pharmaceutical Biotechnology and Advanced Therapies”. Isabelle performs her research work as a member of INSERM 996 “Inflammation, Microbiome, and Immunosurveillance” Laboratory. Her field of interest deals with the immunogenicity of biotherapeutics, as she develops cellular models to assess the potential of aggregated therapeutic proteins to induce immune responses. She’s now interested in the description of cellular mechanisms involved in the activation of dendritic cells by the aggregates, along with the description of the switch towards adaptive immune responses, allowing the production of anti-drug antibodies. As such, she was part of the European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK, receiving support from the Innovative Medicine Initiative, 2012-2018). She is currently part of the French program France 2030, within the consortium ACCREDIA (ACCelerating Research for Early Development of Innovative Antibodies).

• Protein Stability & Formulation

Obinna leads the immunology drug discovery and development at Elasmogen Limited. He holds a PhD in Molecular Biology and Antibody, and has more than a dozen peer reviewed publications and several patents.

• Engineering Conjugates

Sandra Uhlenbroich is Associate Director at Bicycle Therapeutics which she joined in 2019. Having previously led a team leveraging Bicycle’s unique phage-display platform to advance Bicycle’s internal oncology pipeline and partnered programs, Sandra currently oversees the internal early-stage project portfolio as Discovery Project Leader. Prior to joining Bicycle Therapeutics, Sandra worked at F-star Therapeutics where she led bispecific antibody immune-oncology projects up to candidate stage. She holds a PhD in Biochemistry from the University of Toulouse (France).

• Engineering Conjugates

Joost Uitdehaag is an accomplished expert in oncology drug discovery, both in the antibody and small molecule field. Before joining Crossfire Oncology, he led early discovery teams at Schering-Plough, MSD and AstraZeneca. He is founding member of an oncology-based biotech company, and chaired the development team at LAVA Therapeutics that brought a bispecific antibody into Phase I. As Head of Biology at Crossfire, he is bridging the targeting possibilities of small molecule oncology with the high therapeutic window of antibody therapies by developing new degrader-antibody-conjugates.

• Engineering Antibodies & Beyond

The research group of Dr. van Egmond studies antibody activation of innate myeloid immune cells, macrophages and neutrophils, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology. Her research focuses specifically on (1) the contribution of abnormal antibody responses to chronic inflammation and autoimmunity and (2) monoclonal antibody therapy of cancer. Dr. van Egmond’s research is highly translational and she has a cross appointment with the Department of Surgery and the Department of Molecular Cell Biology and Immunology, to facilitate the rapid progression of preclinical findings into clinical applications.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

After graduating from the University of Ghent, Belgium (BPharm), I gained a PhD in Biochemistry at the University of Sheffield Medical School, in 2001. This was followed by several post-doctoral positions, spanning extracellular matrix biology, as well as bacterial toxin research, before joining Professor Durrant’s cancer immunotherapy lab, generating cancer-targeting anti-glycan antibodies. This led to a research programme on antibody Fc-engineering, after which I swapped Academia for Biotech by joining Scancell Ltd. In my current role, I oversee Scancell’s cancer glycan-targeting antibody products (GlyMabTm), and the AvidiMab technology for improved antibody functionality.

• Antibody-Based Cancer Therapies

Electrotechnical Engineer with Software degree. Working in Pharmaceutical Market since 1996. Working in HSG since 2009 as Director and starting from 1 April 2024 as Managing Director. Strong experience in data analysis. Married, two daughters, two cats, and in my free time I like to cook and drink good wine.

• Using Data Science to Maximise Protein Production

Vedran Vasic is a Scientist in the Large Molecule Research division at Roche Pharma Research and Early Development (pRED) in Penzberg, Germany. His work focuses on protein and antibody engineering, bi- and multi-specific antibodies, and conditionally active antibody derivatives. Vedran joined Roche pRED in 2020 as a Roche Postdoctoral Fellow (RPF), where he developed novel platforms for conditional activation of bispecific antibodies and antibody-cytokine fusions. Before joining Roche, he completed his PhD at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. During his PhD, he investigated molecular pathways involved in protein quality control at the endoplasmic reticulum, with a focus on membrane protein biochemistry.

• Antibody-Based Cancer Therapies

Dr. Vázquez-Abad is recognized as a skilled teacher and mentor; through over two decades at Pfizer she has created and presented educational materials to colleagues at Pfizer and to external audiences covering topics such cytokine signaling, immunogenicity, drug development process, immuno-oncology, and mechanism of action of drugs. Some of her talks are available in her YouTube Channel. Dr. Vázquez-Abad graduated as a medical doctor from the National Autonomous University of Mexico (UNAM). She began her career providing patient care in socially marginalized communities around Mexico City’s “poverty belt” and later she spent a year as a resident in the Southeast Jungle of Mexico, living among and treating underserved communities. She did her residency in Internal Medicine at the Hospital de Petróleos Mexicanos in Mexico City and her rheumatology fellowship at the National Institute of Cardiology in Mexico. She further trained in cellular, humoral, and molecular immunology at University of Texas Southwestern, and Cold Spring Harbor Laboratories, NY USA completing a post-doctoral fellowship in rheumatology at the University of Connecticut Health Center in the USA, where she became an Assistant Professor until joining Pfizer in 1998 as clinical lead and in 2007 she was the Inflammation Therapeutic Area Clinical Lead, managing a portfolio of over 15 compounds. From 2009 to 2014 she became the development lead of the inflammation portfolio for the Emerging Market countries. In 2014 she became Vice President, Chief Medical Officer of the Immunoscience Research Unit in Pfizer at Cambridge, Massachusetts, and later Chief Medical Head of Clinical Research, at the Immunology and Inflammation Research Unit. In 2015, she joined the Biosimilars teams as Head of Clinical and in 2019, she became the I&I Global Clinical Lead across the Biosimilars portfolio; in 2022 she became Medicine Team Leader, Clinical Immunogenicity, Pfizer, Cambridge, MA, leading the Immunogenicity Clinical Interpretation and she co-chairs Immunogenicity Advisory Council at Pfizer.

• SC6: Introduction to Immunogenicity of Biotherapeutics

Rodrigo Vazquez-Lombardi is co-founder and CSO of Engimmune Therapeutics. His research for over a decade has focused on the molecular engineering and development of immunotherapies including cytokine, antibody and T cell receptor (TCR) therapeutics. During his doctoral studies, Rodrigo discovered a novel mechanism of action of interleukin-2-Fc fusion proteins against cancer, namely Treg depletion. As a PHRT Postdoctoral Fellow at ETH Zurich, he established the TCR-Engine platform combining CRISPR-Cas9 genome editing, mammalian display, deep sequencing and computational methods for TCR engineering, as well as additional platform technologies now licensed to Engimmune, which he co-founded in August 2021. As CSO at Engimmune, he leads a multidisciplinary team applying AI-guided engineering of soluble TCR therapeutics for oncology indications of high unmet medical need. Rodrigo holds a BSc (Hons I) degree from the University of Sydney and a PhD from the University of New South Wales (Garvan Institute).

• Antibody-Based Cancer Therapies

Salvador Ventura is Full Professor at the Dept. of Biochemistry and Molecular Biology and leader of the Protein Folding and Conformational Diseases group at the Institute of Biotechnology and Biomedicine (IBB), Autonomous University of Barcelona (UAB). He has been director of the IBB in 2017-20. He has authored >270 peer-reviewed research and review papers, >20 book chapters, and 17 patents. He got his Ph.D. in Biology at the UAB in 1998 and worked as postdoctoral fellow (1999-2002) at EMBL-Heidelberg. He has been researcher at Harvard Medical School (USA) and Karolinska Institutet (Sweden) among other centres. He rejoined UAB as a Ramon y Cajal researcher in 2003. Dr. Ventura received the UAB 2008 Excellence Research Award, the Bruker Prize "Manuel Rico" 2020 from the Spanish Biophysical Society, the 2009, 2015, and 2020 ICREA-Academia Awards in Life Sciences and Medicine, the UAB 2022 Transference Award and the 2022 Narcis Monturiol Medal and is a member of Academia Europaea. He is co-founder of Eureka NanoBioEngineering.

• Protein Stability & Formulation

Yvonne Vercoulen is a principal investigator and associate professor at the Center for Molecular Medicine of the UMC Utrecht and a member of the Utrecht Young Academy. Throughout her career she has developed a fascination for immune regulation and aims to understand how errors result in tissue inflammation and cancer. She trained as a PhD student in T cell immune regulation at Utrecht University, and as a Marie-Curie international postdoctoral fellow in T cell receptor signal transduction at UC San Francisco. Dr. Vercoulen’s team at the UMC Utrecht works at the interface of immunology and cancer to identify cellular and molecular underpinnings of disease using spatial omics technology. The Vercoulen lab asks fundamental questions to, for example, understand how immune cells contribute to cancer development, prognosis and therapy response. The team has developed multiplex spatial analyses technology integrating microscopy with imaging mass cytometry and applies both protein and spatial RNA multiplex analyses to investigate the interplay between different cell types in the tissue. Studying tissue and intercellular communication in the tumor microenvironment is essential to understand the mechanisms of disease and therapy response. Dr. Vercoulen’s team collaborates closely with clinicians and researchers from multiple disciplines and strives to drive the field of spatial tissue biology forward and bring this to a level of clinical application.

• Modulating the Tumour Microenvironment

Jessica Vogel is a key member of the team at CSL Innovation GmbH, where she works on the development of downstream processes for lentiviral vectors. After completing her apprenticeship in 2013, she began her career in recombinant process development. In 2020, Jessica made the switch to the lentiviral process development lab, where she also completed her Bachelor's degree. In addition to process development, Jessica is responsible for downstream scale-up and process transfer to the production sites. Jessica holds a Bachelor of Science in Molecular Biology from the Johannes-Gutenberg-University in Mainz.

• Protein Process Development

Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. Bjørn was team leader in the biotech company Pharmexa A/S, responsible for molecular cloning and expression of protein-based drug candidates. From this, he went to the NNF Center for Protein Research at the University of Copenhagen as Head of the Protein Production Unit, and, since 2012, Bjørn has been heading the CHO Cell Line Engineering project dedicated to the engineering of improved protein production cell factories, and since 2021 he has been heading the Cell Line and Protein Production in the National Biologics Facility at the Technical University of Denmark.

• Protein Process Development
• Optimising Expression Platforms

Eric Voltà-Durán graduated in biotechnology in 2018 and pursued Master studies in advanced nanoscience and nanotechnology (2019). He obtained his PhD in Biotechnology in 2023, under the title of “Exploring and exploiting multi-domain recombinant proteins as targeted nanomedical tools”. He is a young, early-stage researcher working at the Nanobiotechnology group, a team led by Professor Antonio Villaverde and Dr. Esther Vázquez at Autonomous University of Barcelona. As a postdoctoral researcher, he is currently focused on the design and production of proteins with biomedical interest, especially in the context of targeted therapies. He is coauthor of 25 scientific papers, most of them products of his intense collaboration with international researchers and other excellent Spanish groups in the context of CIBER-BBN, a consortium to which he belongs. His research on targeting cancer-associated fibroblasts has also contributed to the generation of one patent.

• Optimising Expression Platforms

Saša Vrhovec Hartman earned her PhD in Biomedicine from the University of Ljubljana, Slovenia, with a focus on theoretical and experimental biophysics of lipid membranes and microfluidics. In 2022, she joined Novartis and currently holds the position of Senior Expert Science Technology in Process Analytical Expert team, based in Slovenia.

• Analytical Characterisation of Biotherapeutics

Sally Ward completed her PhD research in the Department of Biochemistry at Cambridge University in 1985 under the mentorship of Professor David Ellar. From 1988 to 1990, she carried out research on antibody repertoire technology in Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology in Cambridge. In 1990 she joined the University of Texas Southwestern Medical Center, Dallas, as an Assistant Professor. From 2002-2014, she was a Professor in the Department of Immunology at the same institution and in 2004 was appointed to the Paul and Betty Meek-FINA Professorship in Molecular Immunology. Since 2014, she has been a Professor at Texas A&M University Health Science Center, and has recently been appointed as Director of Translational Immunology and Professor of Molecular Immunology at the Centre for Cancer Immunology in Southampton, U.K. In 2010, she was a founding co-organizer of the Gordon Research Conference ‘Antibody Biology and Engineering’. She is currently vice president of the Antibody Society. Her interdisciplinary research involves the use of a combination of fluorescence imaging, protein engineering and in vivo studies to develop antibody-based therapeutics to treat cancer and autoimmunity.

• Display of Biologics

Dr. Christopher Wassif has a wide breadth of knowledge having spent 27 years working at the National Institutes of Health, Bethesda, USA in the fields of Genetics, Rare Diseases, Biomarker discovery/validation, and high throughput small molecule screening. With 90 plus peer reviewed manuscripts and multiple book chapters he is a well-respected leader in multiple fields of research. In 2022, Dr. Wassif transitioned to AstraZeneca as Director of Molecular Engineering and Antibody Technologies and global lead for the Machine Learning for Antibody and Biologics (MLAB). In his current role he leads a dynamic team of scientist converging the powers of AI/ML to facilitate and accelerate biologic discovery.

• Display of Biologics

Research scientist at Engimmune Therapeutics since 2022. PhD thesis at EPFL in protein design and immunoengineering.

• Optimisation & Developability

Jennifer Wei is an expert in the applications of machine learning to chemical and biological sciences. She earned her PhD from Harvard University in Chemical Physics, for her dissertation, she developed machine learning algorithms for reaction prediction and mass spectrometry. She later joined Google Brain Research where she developed models for chemical olfaction, mosquito repellency, and nanobody functionality. Jennifer is now lead software engineer on the OpenFold Project, building open source machine learning models for protein structure prediction.

• Machine Learning Approaches for Protein Engineering: Part 1

Background in biochemistry and over 7 years of experience in biologics analytics covering research and development in Biotech and Big Pharma. Particularly involved in setting up and validating meaningful Developability assessment platforms and with a strong interest in using data science and automation to get the most out of our assays and analytical results for early and late stage biologics development.

• Protein Stability & Formulation

Nina Weisser is Director of Multispecific Therapeutics at Zymeworks where she leads a research team in the development of multispecific antibody therapeutics with a focus on mechanism of action studies. Since joining Zymeworks in 2012, she has led several research programs, including zanidatamab from discovery to early development. She received her PhD from the University of Guelph and held a post-doctoral fellowship at the National University of Ireland, Galway.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

No bio available.

• Machine Learning Approaches for Protein Engineering: Part 2

Trevor is Director in the Department of Biologics Engineering at AstraZeneca. In this role Trevor is responsible for the Protein Sciences Technology Platform Team which delivers high quality Target Proteins and Engineered Cell Lines to Biologics Projects across diverse therapy areas. His previous positions include Associate Director of Protein Sciences at MedImmune, Head of Protein Sciences at Cambridge Antibody Technology and Biochemistry Team Leader at Roche Products Ltd. Trevor holds a PhD in Protein Biochemistry from the University of Southampton and an MBA from the University of Hertfordshire.

• Antibodies Against Membrane Protein Targets

Chris took his undergraduate degree in Molecular and Cellular Biology at the University of Glasgow. He then went on to undertake a PhD and postdoc in the lab of Professor Dek Woolfson, where he worked on developing and applying tools for computational protein design. In 2018, he was awarded an EPSRC postdoctoral fellowship and moved to the University of Edinburgh to establish his research group. In 2020, he attained a permanent position in the School of Biological Science as a Lecturer in Biotechnology, before being promoted to Senior Lecturer in 2024.

• Using Data Science to Maximise Protein Production

Dr. Wu is the head of the Protein Sciences department, responsible for operations and strategy. Prior to WuXi Biologics, he worked for more than 15 years at Genentech and Celera on over 50 drug development programs. His expertise includes automated expression, purification, and characterization of diversified proteins such as antibodies, antigens, enzymes, and complex recombinant proteins. Dr. Wu received his Ph.D. from Shanghai Institute of Biochemistry and his Post-Doctoral at UCLA.

• Emerging Targets and Therapeutic Approaches

David is a Principal Scientist at Alchemab Therapeutics with 15 years of experience in both academia and industry. While working in biopharmaceutical companies, he has developed expertise in antibody discovery, biologics engineering and next generation sequencing technologies. At Alchemab, he has been integral to building and innovating the platform. He leads a team working on advanced methods for sequencing patient immune repertoires and identifying antibody targets.

• Emerging Targets and Therapeutic Approaches

Dr. Bei-Wen Ying has over 15 years of interdisciplinary research experience. Her latest work focuses on discovering the law in cell growth using data science approaches, particularly in applying machine learning models to optimize cell culture media. Dr. Ying completed her Ph.D. in Biosciences from the University of Tokyo and worked at CNRS (France) and Osaka University (Japan) before having her lab at the University of Tsukuba (Japan). She published over 50 peer-reviewed papers, primarily as the first or corresponding author, and serves as the editorial board member for multiple highly reputed journals. She leads a team dedicated to acquiring big data from biological experiments to improve the cell growth of both bacteria and mammals. Dr. Ying is also an active mentor for the young academic and industrial scientists entering the field.

• Using Data Science to Maximise Protein Production

Kevin has over 20 years of broad experience in Biologics CMC, and Strategic and Technical Operations. Prior to joining IGM Biosciences, he held various positions in biologics CMC disciplines at Allergan, AnaptysBio, AstraZeneca, Becton Dickinson, and Catalent Biopharma Solutions. In addition to developing therapeutic biological products in-house, Kevin also had extensive experience working with external contract manufacturing organizations (CMO) and contract research organizations (CRO), including production cell line development, bioprocess development, DS/DP cGMP manufacturing, process characterization, process performance qualification (PPQ), formulation development by DoE, analytical procedure development and method validation, reference standard qualification, extended characterization, and CMC analytical comparability.

• TS10A: Introduction to Analytical Characterisation and Method Validation for Biological Products

No bio available.

• Machine Learning Approaches for Protein Engineering: Part 2

Stefan works as Senior Director at Merck Healthcare KGaA (EMD Serono), Germany, where he heads Global Antibody Discovery and Protein Engineering (ADPE). He holds a PhD in chemistry as well as a habilitation in biochemistry. In addition, he is Professor of Biomolecular Immunotherapy at Technical University of Darmstadt.

• Engineering the Next Generation of Bispecific Antibodies

Dominik Zürcher is a PhD researcher in the group of Professor Paolo Arosio at ETH Zürich. Together with an industrial partner, he develops microfluidic techniques and other automatable approaches to assess and optimize the interfacial stability of therapeutic protein formulations. He holds a B.Sc. and M.Sc. degree in chemical and bioengineering from ETH Zürich. During his studies, he interned in the group of Professor Tuomas P. J. Knowles at the University of Cambridge for his master's project to investigate antigen-antibody interactions using microfluidic techniques. After one year of project-based work in the R&D and marketing department of a major consumer goods company, he joined the Biochemical Engineering Laboratory in September 2020 to pursue his PhD studies in collaboration with an industrial partner from the biopharmaceutical industry.

• Protein Stability & Formulation

Senior Clinical Investigator, and Associate Director of the START Madrid-CIOCC unit. Dr. de Miguel has been involved in more than 150 Phase I clinical trials, including First-in-human, First-in-class trials, immunotherapy trials, cell-therapy, biomarker-driven trials, and ADCs with special emphasis on gastrointestinal, head and neck, and thoracic tumors. Dr. de Miguel has co-authored over 40 peer reviewed scientific articles including NEJM, Lancet, Cancer Cell or CCR, among others. She serves as a reviewer of various oncology peer-reviewed journals. She also has taken part of multiple international presentations at different major conferences and meetings such as ASCO, AACR, and ESMO. Dr. de Miguel is a member of ESMO and part of the Scientific Committee in 2024. She also has collaborated as a Faculty Member of the ECCO-AACR-EORTC-ESMO International Workshop in Methods in Clinical Cancer Research (2022-2023), the MCCR International Workshop. From the academic perspective, Dr. de Miguel is Clinical Associated Professor of Medicine at the CEU San Pablo, and the UCJC Universities. She is part of the faculty of different research and medicine training programs, as well as directing MSc and PhD students.

• Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies

Ruud de Wildt joined T-Therapeutics, Cambridge, UK, in 2023, and he is responsible for the discovery of fully human therapeutic TCRs and bispecifics using T-Therapeutics’ novel mouse transgenic platform. Before that he had been at GSK since 2007, and since 2012, he has headed up Antibody Lead Discovery and is responsible for all in vitro and in vivo antibody discovery platforms. He was a founding scientist and Associate Director at Domantis from 2001-2007, which was acquired in 2007, by GSK. He did a postdoc in the lab of Sir Gregory Paul Winter, CBE, FRS, FMedSci (2018 Nobel Prize winner for Chemistry), at the MRC Centre for Protein Engineering and Laboratory of Molecular Biology, Cambridge, UK, from 1998-2001. He completed his PhD in the Department of Biochemistry, Nijmegen, Netherlands, in 1998, and completed a Masters in Biomedical Health Science, at the same University in 1994.

• Engineering the Next Generation of Bispecific Antibodies

Diego del Alamo is a computational biologist in the Protein Design & Informatics group at GSK since May 2022 in Switzerland. He is involved in efforts to design therapeutic antibodies and other proteins. Prior to this, Diego completed his PhD at Vanderbilt University in Nashville, TN, USA where he developed methods in Rosetta and AlphaFold for structural modeling of proteins, such as conformational change modeling, using electron paramagnetic resonance spectroscopy data.

• Machine Learning Approaches for Protein Engineering: Part 1

I am a molecular and cellular biologist in (immuno)oncology research. As a senior scientist and project leader within AUMC Amsterdam and CimCure BV, I focus on tumor angiogenesis. Using molecular profiles of tumor endothelial cells, we develop immunotherapies, including vaccines and CAR T cells, that suppress tumor angiogenesis and overcome endothelial cell anergy (a form of immunosuppression), and result in suppression of cancer growth.

• Innovative CAR T Therapy

Marc van Dijk, PhD, is the Chief Technology Officer at MiNK Therapeutics. He brings more than 25 years of experience leading platform development. He was previously Chief Technology Officer at Agenus and 4-Antibody, a subsidiary of Agenus. Dr. van Dijk was previously Vice President, Antibody Technology at Genmab, and Director of Applied Research at Innogenetics (now Fujirebio). At Medarex and Genmab, he managed partnerships with Immunex (now Amgen), and Roche, and served as project leader on numerous discovery projects including Humax-CD20 (Arzerra). He held a tenure track position in the Department of Immunology at the University Medical Center in Utrecht and completed his postdoctoral fellowship in Molecular Biology at the University of California, San Diego. He obtained his Ph.D. in Molecular Biology from Utrecht University.

• Next-Generation Immunotherapies

Dewald van Dyk is a Group Leader of Biologics Engineering at AstraZeneca Pharmaceuticals LP. He joined MedImmune/AstraZeneca in 2016. His research focuses on the generation of antibodies against pipeline targets including complex integral membrane proteins and other difficult targets using display platforms. He received his PhD training from the University of Stellenbosch, South Africa, and moved on to the University of Toronto, Canada, for post-doctoral training in phage-based antibody discovery, Fc engineering and lead optimization.

• Antibody-Based Cancer Therapies

Pauline van Helden, Ph.D. is heading the translational research department at LAVA Therapeutics. She received her Ph.D. degree from the Utrecht University in Utrecht, the Netherlands in 2007 on immune responses against FVIII in the department of plasma proteins. From 2007 to 2010 she performed post-doctoral research at the division of immunology at Baxter Bioscience in Vienna, Austria after which she worked at AIMM Therapeutics in Amsterdam from 2010 to 2021 as (senior) scientist and director antibody and target discovery using human B-cell immortalization technology. Since 2021 she has joined LAVA Therapeutics focusing on early research and target discovery.

• Next-Generation Immunotherapies

Edward van der Horst, PhD, is a molecular pharmacologist with a strong focus on antibody drug development across diverse target classes in oncology. He has 20 years of research and development experience from Zenith Epigenetics Ltd., Igenica Biotherapeutics, Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen), and U3 Pharma GmbH (now Daiichi-Sankyo). Dr. van der Horst’s contributions and discoveries have led to the clinical evaluation of several novel drug candidates at Igenica Biotherapeutics and OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH. He received his postdoctoral training at Tularik, Inc., earned his PhD in biochemistry from the Max-Planck Institute of Biochemistry and conducted his master’s thesis at Max-Planck Institute of Neurobiology. He graduated with an MS of chemistry from the Ludwig Maximilian University of Munich.

• Antibody-Based Cancer Therapies

After obtaining her master’s degree in the life sciences, Willemijn started as a PhD student in 2018 at the Leiden University Medical Center (LUMC). Her PhD research focused on the antibody-mediated delivery of viral epitopes to redirect virus-specific T-cells towards cancer cells. The project was a collaborative effort of the Cell and Chemical Biology department and the Hematology department within the LUMC, the Leiden institute of Chemistry and Genmab.

• Engineering the Next Generation of Bispecific Antibodies